<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11608245</article-id><article-id pub-id-type="pmcid-ver">PMC11608245.1</article-id><article-id pub-id-type="pmcaid">11608245</article-id><article-id pub-id-type="pmcaiid">11608245</article-id><article-id pub-id-type="pmid">39616189</article-id><article-id pub-id-type="doi">10.1038/s41598-024-76189-0</article-id><article-id pub-id-type="publisher-id">76189</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A multicenter trial on the predictors of different subtypes of hemorrhagic infarction after thrombolysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zeinhom</surname><given-names initials="MG">Mohamed G.</given-names></name><address><email>mohamed_gomaa@med.kfs.edu.eg</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ahmed</surname><given-names initials="SR">Sherihan Rezk</given-names></name><address><email>sherihan_rezq@med.kfs.edu.eg</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kohail</surname><given-names initials="AM">Ahmed Mohamed</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kamel</surname><given-names initials="IFM">Islam Fathallah Mohamed</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdelrahman</surname><given-names initials="AM">ALshimaa Mahfouz</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>AL-Nozha</surname><given-names initials="OM">Omar M.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Almoataz</surname><given-names initials="M">Mohamed</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Youssif</surname><given-names initials="TYO">Tarek Youssif Omar</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Daabis</surname><given-names initials="AMA">Ahmed Mohamed Ali</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Refat</surname><given-names initials="HM">Hossam Mohamed</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ebied</surname><given-names initials="AAMK">Ahmed Ahmed Mohamed Kamal</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Elbassiouny</surname><given-names initials="A">Ahmed</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Akl</surname><given-names initials="AZO">Ahmed Zaki Omar</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shuaib</surname><given-names initials="A">Ashfaq</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ismaiel</surname><given-names initials="M">Mohamed</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ibrahem</surname><given-names initials="AIDM">Asmaa Ibrahem Desouky Mostafa</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khalil</surname><given-names initials="MFE">Mohamed Fouad Elsayed</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.411978.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0578 3577</institution-id><institution>Neurology Department, faculty of medicine, </institution><institution>Kafr El-sheikh university, </institution></institution-wrap>Elgeish street, Kafr el-sheikh, Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05fnp1145</institution-id><institution-id institution-id-type="GRID">grid.411303.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2155 6022</institution-id><institution>Neurology Department, faculty of medicine, </institution><institution>Al-Azhar university, </institution></institution-wrap>ELmokhaim St., Cairo, Egypt </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/016jp5b92</institution-id><institution-id institution-id-type="GRID">grid.412258.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9477 7793</institution-id><institution>Neurology Department, faculty of medicine, </institution><institution>Tanta university, </institution></institution-wrap>ELbahr St., Tanta, Egypt </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02hcv4z63</institution-id><institution-id institution-id-type="GRID">grid.411806.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 8999 4945</institution-id><institution>Radiology Department, faculty of medicine, </institution><institution>ELminia university, </institution></institution-wrap>ELgomhoria St., Minya, Egypt </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01xv1nn60</institution-id><institution-id institution-id-type="GRID">grid.412892.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1754 9358</institution-id><institution>Medicine Department, College of Medicine, </institution><institution>Taibah University, </institution></institution-wrap>23 ELhars st., Madina, Saudi Arabia </aff><aff id="Aff6"><label>6</label>Neurology Department, Saudi German hospital, Sharjah, United Arab Emirates </aff><aff id="Aff7"><label>7</label>Neurology Department, Burjeel medical city Abu Dhabi, Abu Dhabi, United Arab Emirates </aff><aff id="Aff8"><label>8</label>Neurology Department, Burjeel Royal Hospital Al Ain, Al Ain, United Arab Emirates </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/053g6we49</institution-id><institution-id institution-id-type="GRID">grid.31451.32</institution-id><institution-id institution-id-type="ISNI">0000 0001 2158 2757</institution-id><institution>Neurology Department, </institution><institution>Faculty of medicine Zagazig university, </institution></institution-wrap>2 elgeish Et, Zagazig, Egypt </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00cb9w016</institution-id><institution-id institution-id-type="GRID">grid.7269.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0621 1570</institution-id><institution>Neurology department, faculty of medicine, </institution><institution>Ain shams university, </institution></institution-wrap>ELabbasia St., Al khalifa elmamon St., Cairo, Egypt </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0160cpw27</institution-id><institution-id institution-id-type="GRID">grid.17089.37</institution-id><institution>Division of neurology, department of medicine, </institution><institution>University of Alberta, </institution></institution-wrap>Clinical sciences building, Edmonton, AB T6G 2R3 Canada </aff><aff id="Aff12"><label>12</label>Neurology Department, El-Sahel Teaching hospital, 2 Yossef Karam, El Sahel, Cairo, 11697, Egypt </aff><aff id="Aff13"><label>13</label>Neurology Department Al-Raml Hospital, Alexandria, Egypt </aff><aff id="Aff14"><label>14</label>Neurology Department, Saudi German hospital Madinah, 23 ELhars St., Madina, Saudi Arabia </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">452196</issue-id><elocation-id>29822</elocation-id><history><date date-type="received"><day>1</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-02 07:25:36.030"><day>02</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2024_Article_76189.pdf"/><abstract id="Abs1"><p id="Par1">Worldwide, stroke is a leading cause of long-term disability in adults. Alteplase is the only approved treatment for acute ischemic stroke (AIS) and results in an improvement in a third of treated patients. Most studies evaluated the post-alteplase haemorrhagic transformation of brain infarction as a homogeneous entity but we evaluated the predictors of each subtype of haemorrhagic transformation of brain infarction. Our trial included 616 AIS alteplase-treated patients. We evaluated the ability of different risk factors, clinical presentation, and imaging features to predict different haemorrhagic transformation (HT) subtypes. HT was seen in 152 patients (24.7%), higher NIHSS, cardioembolic stroke and atrial fibrillation were independent predictors of all ECASS-based subtypes of hemorrhagic infarction, in addition, anterior-circulation stroke was an independent predictor of hemorrhagic infarction type 1 (odds ratio [OR], 11.04; 95% CI, 9.81 to 12.70; P-value&#8201;&gt;&#8201;0.001) and type2 (OR, 11.89; 95% CI, 9.79 to 14.44; P-value&#8201;&gt;&#8201;0.001), while older age was also an independent predictor of parenchymal hematoma type1 (OR, 1.312; 95% CI, 1.245 to 1.912; P-value 0.02). In AIS patients treated with alteplase in Egypt and Saudi Arabia, higher NIHSS, cardioembolic stroke and atrial fibrillation were independent predictors of all ECASS-based subtypes of hemorrhagic infarction; in addition, anterior-circulation stroke was an independent predictor of hemorrhagic infarction type 1 and 2, while older age was also an independent predictor of parenchymal hematoma type1. Trial registration: (clinicaltrials.gov <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06337175">NCT06337175</ext-link>), retrospectively registered on 29/03/2024.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alteplase</kwd><kwd>Hemorrhagic infarction</kwd><kwd>Egypt</kwd><kwd>Saudi Arabia</kwd><kwd>Middle east</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Stroke</kwd><kwd>Neurological disorders</kwd></kwd-group><funding-group><award-group><funding-source><institution>Kafr El Shiekh University</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par21">Stroke is a leading cause of long-term disability in adults. It ranks as the second leading cause of mortality on a global scale. Developing countries bear a disproportionate burden of stroke, representing 66% of the total stroke cases worldwide<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>.</p><p id="Par22">Although intravenous thrombolysis with alteplase significantly improves long-term outcomes after ischemic stroke, it may produce hemorrhagic transformation of the infarction, which occurs in up to 5% of the patients, increasing post-stroke mortality and morbidity<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>.</p><p id="Par23">The risk of HT increases with large core infarction, older age, hyperglycemia, the use of anticoagulation, and the presence of small vessel disease or cerebral microbleeds. The presence of HT can lead to a significant increase in post-stroke mortality<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par24">Although many studies evaluated the prevalence and risk factors for HT in patients treated with alteplase and showed that the prevalence of HT in patients treated with alteplase globally was 32% and in East Asia was 35%<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, very little information on factors that contribute to HT in the Arab population, in this study, our objective was to assess the factors predicting ECASS-based different subtypes of post-alteplase haemorrhagic transformation in patients from the Middle East who have experienced ischemic stroke.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Trial design</title><p id="Par25">We conducted our prospective open-label trial between June 2022 and October 2023 after receiving the appropriate ethical committee approvals.</p><p id="Par26">All methods were performed in accordance with the relevant guidelines, regulations and declaration of Helsinki.</p></sec><sec id="Sec4"><title>Participants</title><p id="Par27">Our study included 616 first-ever AIS patients treated with alteplase within four and half hours of which 248 patients were recruited from Kafr el-Sheikh, 254 patients from Nasr City insurance hospitals in Egypt, and 114 patients from Saudi German hospitals in Madinah, Saudi Arabia.</p><p id="Par28">Before inclusion in our study, we got formal written informed consent from all eligible patients or their first order of kin.</p><p id="Par29">The study consisted of five distinct groups. The first group consisted of 464 patients who did not experience haemorrhagic transformation, the second group comprised 73 patients who had HT type1, the third group comprised 54 patients who had HT type2, the fourth group comprised 14 patients who had PH type1, and the fifth group comprised 11 patients who had PH type2.</p><p id="Par30">Our study adheres to CONSORT guidelines and includes a completed CONSORT checklist as an additional file.</p></sec><sec id="Sec5"><title>Inclusion criteria</title><p id="Par31">We enrolled individuals of both genders, aged 18 to 75 years, who presented with their first-ever acute ischemic stroke and were eligible to receive alteplase as they presented within 3- to 4.5-hours, without a history of prior stroke in the past three months, NIHSS score&#8201;&#8804;&#8201;25, not taking any oral anticoagulants in the past 24&#160;h, and without imaging evidence of intracranial hemorrhage<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par32">The diagnosis was made based on clinical history, physical examination, and specific findings from brain imaging. The study did not exclude patients who had experienced previous transient ischemic episodes (TIA). Only patients treated with alteplase were included in the study.</p><p id="Par33">We excluded patients&#8201;&gt;&#8201;75 years old as advancing age is associated with an increased risk of HT, as well as worse stroke outcomes. Older patients experience an increase in systemic inflammation and blood-brain barrier (BBB) permeability and have a more significant burden of cerebrovascular disease, hypertension and diabetes, which induce inflammation and atherosclerosis, so if a stroke occurs, the age-related inflammation produces blood-brain barrier disruption leading to an increased risk of HT<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par34">Also patients older than 75 years old have higher possibility of atrial fibrillation which necessitates anticoagulation and limits the use of alteplase<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p></sec><sec id="Sec6"><title>Exclusion criteria</title><p id="Par35">Patients excluded from the study were those who had contraindications to alteplase such as patients whose CT of the brain revealed an acute intracranial hemorrhage, patients who had a prior ischemic stroke within 3 months, patients with recent severe head trauma within 3 months, patients with post-traumatic infarction that occurs during the acute in-hospital phase and AIS patients and a history of intracranial/spinal surgery within the prior 3 months, patients who had a history of intracranial hemorrhage, Patients who had a structural gastrointestinal malignancy or recent bleeding event within 21 days of their stroke event, patients who had platelets&#8201;&lt;&#8201;100 000/mm3, INR&#8201;&gt;&#8201;1.7, aPTT&#8201;&gt;&#8201;40&#160;s, or PT&#8201;&gt;&#8201;15&#160;s, patients who received a full treatment dose of LMWH within the previous 24&#160;h, patients who received direct thrombin inhibitors or direct factor Xa inhibitors, patients who had symptoms consistent with infective endocarditis, and patients who had AIS who harbor an intra-axial intracranial neoplasm<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. We ruled out patients who did not receive the complete dose of alteplase and those who had a documented medical history of chronic or recurring central nervous system disorders such as epilepsy, meningioma, multiple sclerosis, or a history of head trauma resulting in lasting neurological impairment.</p><p id="Par36">We ruled out Patients who had major organ failure, ongoing malignancies, or a myocardial infarction during the preceding six weeks.</p><p id="Par37">We excluded pregnant and lactating patients and individuals with stroke resulting from venous thrombosis or stroke following cardiac arrest or severe hypotension.</p></sec><sec id="Sec7"><title>Study procedures</title><p id="Par38">The data collected encompassed many demographic and clinical variables, including age, sex, medical history of hypertension (HTN), ischemic heart disease (IHD), hyperlipidemia, diabetes mellitus, cigarette use, treatment history and the duration between symptom onset and treatment initiation.</p><p id="Par39">The diagnosis of ischemic stroke was established through a detailed clinical history and examination and suitable brain imaging. All of our patients had CT of the brain and CT angiography (CTA) including the aortic arch through the circle of Willis before thrombolysis; the CT of the brain was performed on the 64-slice dual-source spiral CT scanner of Somatom definition by Siemens, and the supratentorial compartment scans were imaged with 5&#8211;8&#160;mm contiguous sections and the brain stem and cerebellum scans were imaged with 3&#8211;5&#160;mm slices, and we obtained eighteen images for each series. After thrombolysis, all of our patients underwent an MRI brain on a 1.5 T (Siemens Essenza) MR system, stroke protocol: T1W, T2W, fluid attenuation inversion recovery imaging (FLAIR), diffusion-weighted imaging (DWI), T2 Echo Gradient, and MRA brain &amp; neck time of flight (TOF) if CTA was contraindicated and in our study 33 (5.4%) patients underwent MRA (TOF) brain&amp; neck instead of CTA as they had renal impairment; we performed an additional brain CT scan after 24&#8211;36&#160;h to evaluate hemorrhagic transformation<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, and we considered hemorrhagic transformation symptomatic if the NIHSS score increased by 4 points or more<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>.</p><p id="Par40">The computed tomography (CT)/ magnetic resonance imaging (MRI) examinations were assessed in our study by two highly experienced professionals: a senior stroke physician and a senior radiologist.</p><p id="Par41">Large-vessel stroke was defined according to the Trial of Org 10,172 in Acute Stroke Treatment (TOAST) classification when patients had clinical and brain imaging findings of &gt;&#8201;50% stenosis or occlusion of at least one of the following arterial segments on computed tomography angiography (CTA) or magnetic resonance angiography (MRA) if CTA was contraindicated: intracranial part of internal carotid arteries, middle cerebral arteries (M1/M2), intracranial portion of vertebral arteries, and basilar artery, and patients had cortical or cerebellar lesions and brain stem or subcortical hemispheric infarcts greater than 1.5&#160;cm in diameter on CT or MRI, and there were no potential sources of cardiogenic embolism<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par42">We diagnosed the Small-vessel stroke according to TOAST classification when the brain imaging showed a brain stem or subcortical lesion which measured&#8201;&lt;&#8201;1.5&#160;cm in its largest diameter, and the patient did not have a cardiogenic embolism or ipsilateral arterial stenosis of &#8805;&#8201;50%<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p><p id="Par43">Posterior-circulation stroke (PCS) was defined as symptomatic ischemia occurring in the vascular area of the vertebral, basilar, or posterior cerebral arteries. Anterior-circulation stroke (ACS) manifests symptomatic ischemia within the internal carotid, middle, or anterior cerebral arteries; in addition, we assessed the baseline Alberta Stroke Program Early CT score (ASPECTS) of all patients included in our study, which is a 10-point quantitative topographic CT scan score used in patients with middle cerebral artery (MCA) stroke. A segmental assessment of the MCA vascular territory is made, and 1 point is deducted from the initial score of 10 for every region involved: caudate, putamen, internal capsule, and insular cortex; in posterior circulation stroke, we used pc-ASPECTS which is a 10 point scale, where points are lost for each region affected, thalami (1point each), occipital lobes (1 point each), midbrain (2 points), pons (2 points), and cerebellar hemispheres (1 point each)<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Questionable imaging is imaging whose ASPECT score disagreed with the senior neurologist&#8217;s and the senior radiologist&#8217;s, and the disagreement was settled by reaching a consensus decision.</p><p id="Par44">In our study, we divided cerebrovascular vessels into segments: supra-clinoid internal carotid artery, first-division middle cerebral artery (M1), second-division middle cerebral artery (M2), first-division anterior cerebral artery (A1), second-division anterior cerebral artery (A2), basilar artery (B.A.), intracranial vertebral artery (V.A.), first division posterior cerebral artery P1), and second division posterior cerebral artery (P2). If one or more vascular segments were occluded and the patient was eligible for endovascular management, pre-stroke mRS score of 0&#8211;1<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>; causative occlusion of the internal carotid artery or MCA segment 1 (M1)<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>; age&#8201;&#8805;&#8201;18 years<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>; NIHSS score of &#8805;&#8201;6<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>; ASPECTS of &#8805;&#8201;6; and Ref.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> treatment can be initiated (groin puncture) within 6&#8211;16&#160;h of symptom onset<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Then, the procedure was done by a senior neuro-intervention consultant using Philips Biplane Allura Xper FD20/15 release 8.2 with X-ray generator 100 kva, and the procedure was performed under general anesthesia in an angiography suite with biplane digital subtraction and road-mapping capabilities.</p><p id="Par45">In the non-HT group, 27 patients were eligible. They underwent endovascular management, while in the HT groups, ten patients (six patients in the PH-1 and four patients in the PH-2) were candidates for endovascular management but did not undergo endovascular management due to the occurrence of hemorrhagic transformation and sudden deterioration of patient consciousness level just after receiving alteplase<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par46">All the patients underwent trans-esophageal echocardiography, 12-lead routine ECG 24, 24-hour continuous cardiac rhythm monitoring, carotid duplex, and blood pressure assessment. We diagnosed acute hypertensive response when the systolic blood pressure (BP)&#8201;&#8805;&#8201;140&#160;mm Hg or diastolic (BP)&#8201;&#8805;&#8201;90&#160;mm Hg detected on 2 recordings taken 5&#160;min apart within 24&#160;h of stroke symptom onset<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>, renal function, liver functions, coagulation profile, complete blood count, fasting, postprandial blood sugar, and HbA1C, and we diagnosed diabetes when fasting plasma glucose level was more than 126&#160;mg/dl, or casual plasma glucose was more than 200&#160;mg/dl, or HbA1C was more than 6.5<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Admission hyperglycemia was diagnosed when admission blood glucose value was more than 140&#160;mg/dL<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. We assessed the lipid profile on admission and diagnosed hyperlipidemia when blood cholesterol was more than 200&#160;mg/dL; triglycerides were more than150mg/dL, LDL-cholesterol was more than100 mg/dL and/or HDL-cholesterol is less than 40&#160;mg/dL)<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. We measured the temperature of all of our participants orally at admission and twice daily during hospitalization (Temp Plus II, Ivac, Giessen, Germany) and diagnosed fever when at least one measurement was &#8805;&#8201;38&#186;C (sub-febrile temperature 37.6&#8211;37.9 &#186;C)<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>.</p><p id="Par47">Patients who experienced fever underwent a chest radiograph and urine analysis. If patients had specific symptoms, we performed cultures for sputum, stool and repeated blood cultures, especially if patients had fevers of unknown origin. We managed patients with fever using one gram of acetaminophen early after hospitalization and specific antibiotics according to culture and sensitivity tests<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>.</p><p id="Par48">Based on AHA/ASA guidelines, inclusion and exclusion criteria for alteplase were established; 0.9&#160;mg/kg of tPA up to a maximum dose of 90&#160;mg was administered intravenously to eligible individuals within 4.5&#160;h of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1&#160;h). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit.</p><p id="Par49">Hemorrhagic transformation was defined according to the European Cooperative Acute Stroke Study (ECASS) as any intracranial hemorrhage on any post-treatment imaging after thrombolysis start and increase of NIHSS by 4 points from baseline or death and classified into hemorrhagic infarction type 1 and 2, and parenchymal hemorrhage type 1 and 2<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>.</p><sec id="Sec8"><title>Primary endpoint</title><p id="Par50">We evaluated the haemorrhagic infarction (HI) type1 predictors at 0 to 36&#160;h after IV alteplase.</p></sec><sec id="Sec9"><title>Secondary endpoint</title><p id="Par51">We evaluated the Predictors of HI type2, parenchymal haemorrhage (PH) type1, and type2 at 0 to 36&#160;h after IV alteplase.</p></sec></sec><sec id="Sec10"><title>Sample size</title><p id="Par52">We employed G-power software to calculate the power of our sample size, which was 90%, given a two-sided confidence level of 95% and an alpha error of 5%.</p></sec><sec id="Sec11"><title>Randomization</title><p id="Par53">We included the cohort of patients who met our inclusion criteria and agreed to participate in the trial and presented to the emergency of the prespecified hospitals during the time period from June 2022 to October 2023, we did not use randomization plan as all the patients received the same treatment.</p></sec><sec id="Sec12"><title>Statistical analysis of the data</title><p id="Par54">We used the IBM SPSS software package, version 20.0 (Armonk, NY: IBM Corp.), to analyze our data and base all efficacy analyses on the per-protocol analysis principle. Both the primary and secondary outcomes underwent separate statistical analyses. Depending on their distribution, as determined by the Shapiro-Wilk test, we described numerical data as means S.D. or median and interquartile range (IQR). We also reported categorical data using numbers and percentages. The Mann-Whitney U test was used to compare the irregularly distributed numerical data, while the Chi-square test was applied to investigate the association between the categorical variables. Alternatively, Fisher&#8217;s Exact or Monte Carlo correction test was applied when more than 20% of the cells had an expected count of less than five. Univariate and multivariate logistic regression analyses evaluated the predictors of different HT subtypes. The significance of the obtained results was judged at the 5% level.</p></sec></sec><sec id="Sec13" sec-type="results"><title>Results</title><p id="Par55">Overall, we screened 1450 patients who came to the emergency with clinical manifestations of stroke. One thousand one hundred eighty patients had an ischemic stroke, of which 460 patients were excluded from the study, as 80 patients were older than 75 years old, 40 patients were younger than 18 years old, 130 patients were on regular use of oral anticoagulants, 105 patients had a previous ischemic stroke in the past three months, 40 patients had platelet count&#8201;&lt;&#8201;100 000/mm3 and 65 patients declined to participate, and 720 agreed to participate, and 616 patients (232 females &amp; 384 males) received the total recommended dose of alteplase. They were included in the per-protocol analysis; only 152 (24.7%) had HT, 73 patients (11.9%) had hemorrhagic infarction type 1, 54 patients (8.8%) had hemorrhagic infarction type 2, fourteen patients (2.3%) had parenchymal hemorrhage type 1, eleven patients (1.8%) had parenchymal hemorrhage type 2, as shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.</p><p id="Par56">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study flow diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e687" position="float" orientation="portrait" xlink:href="41598_2024_76189_Fig1_HTML.jpg"/></fig>
</p><p id="Par57">Regarding the symptomatic clinical deterioration following HT (4-points worsening in NIHSS after treatment compared with baseline)<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, we found that 27 patients in the hemorrhagic infarction type 1 group, 26 patients in hemorrhagic infarction type 2 group, eleven patients in parenchymal hemorrhage type 1 group, and ten patients in parenchymal hemorrhage type 2 group had symptomatic clinical deterioration with P-value 0.002.</p><p id="Par58">Patients with HI type 1 had statistically significantly higher baseline NIHSS and a higher percentage of anterior circulation stroke with P-values&#8201;&lt;&#8201;0.001 and 0.02, respectively. In comparison, Patients with HI type 2 had statistically significantly higher baseline NIHSS with a P-value&#8201;&lt;&#8201;0.001 as shown in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par59">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Patients&#8217; baseline characters HI type1 and type2.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Demographic data</th><th align="left" colspan="1" rowspan="1">(Non-HT group) <italic toggle="yes">N</italic>&#8201;=&#8201;464</th><th align="left" colspan="1" rowspan="1">Hemorrhagic infarction type 1, <italic toggle="yes">N</italic>&#8201;=&#8201;73</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th><th align="left" colspan="1" rowspan="1">Hemorrhagic infarction type 2, <italic toggle="yes">N</italic>&#8201;=&#8201;54</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Gender, no, (percentage)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male, no, (percentage)</td><td align="left" colspan="1" rowspan="1">288.0 (62.1%)</td><td align="left" colspan="1" rowspan="1">43.0 (58.9%)</td><td align="left" colspan="1" rowspan="1">0.61</td><td align="left" colspan="1" rowspan="1">35.0 (64.8%)</td><td align="left" colspan="1" rowspan="1">0.69</td></tr><tr><td align="left" colspan="1" rowspan="1">Age at time of presentation, median (IQR)</td><td align="left" colspan="1" rowspan="1">61.0 (58.0&#8211;66.0)</td><td align="left" colspan="1" rowspan="1">60.0 (55.0&#8211;66.0)</td><td align="left" colspan="1" rowspan="1">0.40</td><td align="left" colspan="1" rowspan="1">60.0 (57.0&#8211;65.0)</td><td align="left" colspan="1" rowspan="1">0.20</td></tr><tr><td align="left" colspan="6" rowspan="1">Location of infarction, no, (percentage)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Anterior circulation, no, (percentage)</td><td align="left" colspan="1" rowspan="1">320.0 (69%)</td><td align="left" colspan="1" rowspan="1">60.0 (82.2%)</td><td align="left" colspan="1" rowspan="1">0.02<sup>*</sup></td><td align="left" colspan="1" rowspan="1">43.0 (79.6%)</td><td align="left" colspan="1" rowspan="1">0.11</td></tr><tr><td align="left" colspan="1" rowspan="1">NIHSS at time of admission, median (IQR)</td><td align="left" colspan="1" rowspan="1">10 (7.3&#8211;17.0)</td><td align="left" colspan="1" rowspan="1">17.0 (14.0&#8211;20.0)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td align="left" colspan="1" rowspan="1">17.0 (12.0&#8211;20.0)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Door to needle time (min.), median (IQR)</td><td align="left" colspan="1" rowspan="1">60.0 (55.0&#8211;66.0)</td><td align="left" colspan="1" rowspan="1">55.0 (55.0&#8211;66.0)</td><td align="left" colspan="1" rowspan="1">0.45</td><td align="left" colspan="1" rowspan="1">55.0 (55.0&#8211;66.0)</td><td align="left" colspan="1" rowspan="1">0.46</td></tr><tr><td align="left" colspan="1" rowspan="1">Time of receiving IV rtPA from stroke onset (min.), median (IQR)</td><td align="left" colspan="1" rowspan="1">174.0 (163.0&#8211;200.0)</td><td align="left" colspan="1" rowspan="1">174.0 (164&#8211;200)</td><td align="left" colspan="1" rowspan="1">0.48</td><td align="left" colspan="1" rowspan="1">175.0 (162&#8211;200)</td><td align="left" colspan="1" rowspan="1">0.58</td></tr><tr><td align="left" colspan="6" rowspan="1">Patients on antiplatelets before stroke</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Aspirin and clopidogrel</td><td align="left" colspan="1" rowspan="1">120.0 (25.9%)</td><td align="left" colspan="1" rowspan="1">17.0 (23.3%)</td><td align="left" colspan="1" rowspan="1">0.64</td><td align="left" colspan="1" rowspan="1">12.0 (22.2%)</td><td align="left" colspan="1" rowspan="1">0.56</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Aspirin</td><td align="left" colspan="1" rowspan="1">114.0 (24.6%)</td><td align="left" colspan="1" rowspan="1">20.0 (27.4%)</td><td align="left" colspan="1" rowspan="1">0.60</td><td align="left" colspan="1" rowspan="1">15.0 (27.8%)</td><td align="left" colspan="1" rowspan="1">0.61</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Clopidogrel</td><td align="left" colspan="1" rowspan="1">90.0 (19.4%)</td><td align="left" colspan="1" rowspan="1">17.0 (23.3%)</td><td align="left" colspan="1" rowspan="1">0.44</td><td align="left" colspan="1" rowspan="1">14.0 (25.9%)</td><td align="left" colspan="1" rowspan="1">0.15</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Ticagrelor</td><td align="left" colspan="1" rowspan="1">15.0 (3.2%)</td><td align="left" colspan="1" rowspan="1">2.0 (2.7%)</td><td align="left" colspan="1" rowspan="1">0.82</td><td align="left" colspan="1" rowspan="1">2.0 (3.7%)</td><td align="left" colspan="1" rowspan="1">0.85</td></tr><tr><td align="left" colspan="6" rowspan="1">Patients on anticoagulants before stroke</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Warfarin</td><td align="left" colspan="1" rowspan="1">18.0 (3.9%)</td><td align="left" colspan="1" rowspan="1">3.0 (4.1%)</td><td align="left" colspan="1" rowspan="1">0.93</td><td align="left" colspan="1" rowspan="1">2.0 (3.7%)</td><td align="left" colspan="1" rowspan="1">0.95</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Rivaroxaban</td><td align="left" colspan="1" rowspan="1">14.0 (3.0%)</td><td align="left" colspan="1" rowspan="1">2.0 (3.0%)</td><td align="left" colspan="1" rowspan="1">0.90</td><td align="left" colspan="1" rowspan="1">1.0 (1.9%)</td><td align="left" colspan="1" rowspan="1">0.63</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Apixaban</td><td align="left" colspan="1" rowspan="1">10.0 (2.2%)</td><td align="left" colspan="1" rowspan="1">1.0 (1.4%)</td><td align="left" colspan="1" rowspan="1">0.66</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">IQR</italic> inter-quartile range, <italic toggle="yes">p</italic> p value, *Statistically significant at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05, <italic toggle="yes">HI</italic> hemorrhagic infarction.</p></table-wrap-foot></table-wrap>
</p><p id="Par60">Regarding the analysis of the different risk factors, patients with HI type1 and 2 had a statistically significant higher percentage of atrial fibrillation, large-vessel stroke, and cardio-embolic stroke with a P-value of &lt;&#8201;0.001, &lt;&#8201;0.001, &lt; 0.001, &lt;&#8201;0.001, &lt;&#8201;0.001, and &lt;&#8201;0.001, respectively and a statistically significant lower percentage of small-vessel stroke with P-value 0.002&amp; 0.003, respectively as shown in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par61">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Comparison between the non-HT patients and HI type 1 and 2 patients&#8217; risk factors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Risk factor, no, (percentage)</th><th align="left" colspan="1" rowspan="1">Non-HT group, <italic toggle="yes">N</italic>&#8201;=&#8201;464</th><th align="left" colspan="1" rowspan="1">HI type 1, <italic toggle="yes">N</italic>&#8201;=&#8201;73</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th><th align="left" colspan="1" rowspan="1">HI type 2, <italic toggle="yes">N</italic>&#8201;=&#8201;54</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Hyperlipidemia</td><td align="left" colspan="1" rowspan="1">156.0 (33.6%)</td><td align="left" colspan="1" rowspan="1">24.0 (32.9%)</td><td align="left" colspan="1" rowspan="1">0.90</td><td align="left" colspan="1" rowspan="1">18.0 (33.3%)</td><td align="left" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes mellitus</td><td align="left" colspan="1" rowspan="1">164.0 (35.3%)</td><td align="left" colspan="1" rowspan="1">25.0 (34.2%)</td><td align="left" colspan="1" rowspan="1">0.86</td><td align="left" colspan="1" rowspan="1">20.0 (37.0%)</td><td align="left" colspan="1" rowspan="1">0.81</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td align="left" colspan="1" rowspan="1">288.0 (62.1%)</td><td align="left" colspan="1" rowspan="1">47.0 (64.4%)</td><td align="left" colspan="1" rowspan="1">0.70</td><td align="left" colspan="1" rowspan="1">32.0 (59.3%)</td><td align="left" colspan="1" rowspan="1">0.69</td></tr><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation</td><td align="left" colspan="1" rowspan="1">67.0 (14.4%)</td><td align="left" colspan="1" rowspan="1">25.0 (34.2%)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td align="left" colspan="1" rowspan="1">20.0 (37.0%)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Ischemic heart disease</td><td align="left" colspan="1" rowspan="1">57.0 (12.3%)</td><td align="left" colspan="1" rowspan="1">7.0 (9.6%)</td><td align="left" colspan="1" rowspan="1">0.51</td><td align="left" colspan="1" rowspan="1">5.0 (9.3%)</td><td align="left" colspan="1" rowspan="1">0.52</td></tr><tr><td align="left" colspan="1" rowspan="1">Admission hyperglycemia</td><td align="left" colspan="1" rowspan="1">140.0 (30.2%)</td><td align="left" colspan="1" rowspan="1">25.0 (34.2%)</td><td align="left" colspan="1" rowspan="1">0.48</td><td align="left" colspan="1" rowspan="1">19.0 (35.2%)</td><td align="left" colspan="1" rowspan="1">0.45</td></tr><tr><td align="left" colspan="1" rowspan="1">Previous TIA</td><td align="left" colspan="1" rowspan="1">131.0 (28.2%)</td><td align="left" colspan="1" rowspan="1">19.0 (26.0%)</td><td align="left" colspan="1" rowspan="1">0.70</td><td align="left" colspan="1" rowspan="1">15.0 (27.8%)</td><td align="left" colspan="1" rowspan="1">0.94</td></tr><tr><td align="left" colspan="6" rowspan="1">Etiology, no, (percentage)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Large artery atherosclerosis</td><td align="left" colspan="1" rowspan="1">68.0 (14.7%)</td><td align="left" colspan="1" rowspan="1">25.0 (34.2%)</td><td align="left" colspan="1" rowspan="1">&lt; 0.001<sup>*</sup></td><td align="left" colspan="1" rowspan="1">20.0 (37.0%)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Cardio-embolism</td><td align="left" colspan="1" rowspan="1">55.0 (11.9%)</td><td align="left" colspan="1" rowspan="1">36.0 (49.3%)</td><td align="left" colspan="1" rowspan="1">&lt; 0.001<sup>*</sup></td><td align="left" colspan="1" rowspan="1">28.0 (51.9%)</td><td align="left" colspan="1" rowspan="1">&lt; 0.001<sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Small artery occlusion</td><td align="left" colspan="1" rowspan="1">152.0 (32.8%)</td><td align="left" colspan="1" rowspan="1">11.0 (15.1%)</td><td align="left" colspan="1" rowspan="1">0.002<sup>*</sup></td><td align="left" colspan="1" rowspan="1">7.0 (13.0%)</td><td align="left" colspan="1" rowspan="1">0.003<sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Stroke of undetermined etiology</td><td align="left" colspan="1" rowspan="1">136.0 (29.3%)</td><td align="left" colspan="1" rowspan="1">26.0 (35.6%)</td><td align="left" colspan="1" rowspan="1">0.28</td><td align="left" colspan="1" rowspan="1">20.0 (37.0%)</td><td align="left" colspan="1" rowspan="1">0.24</td></tr><tr><td align="left" colspan="6" rowspan="1">Co-morbid conditions on admission</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Temperature on admission, median (IQR)</td><td align="left" colspan="1" rowspan="1">37.4 (37.2&#8211;37.8)</td><td align="left" colspan="1" rowspan="1">37.6 (37.3&#8211;37.9&#160;)</td><td align="left" colspan="1" rowspan="1">0.41</td><td align="left" colspan="1" rowspan="1">37.6 (37.3&#8211;38.0)</td><td align="left" colspan="1" rowspan="1">0.36</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Cholesterol level on admission, mg/dL, median (IQR)</td><td align="left" colspan="1" rowspan="1">188.0 (181.0&#8211;237.0)</td><td align="left" colspan="1" rowspan="1">194.0 (187.0&#8211;246.0)</td><td align="left" colspan="1" rowspan="1">0.12</td><td align="left" colspan="1" rowspan="1">190.0 (189.0&#8211;245.0)</td><td align="left" colspan="1" rowspan="1">0.31</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean value of two points evaluation of BP within 24&#160;h of symptoms onset, mmHg, median (IQR)</td><td align="left" colspan="1" rowspan="1">145.0 (130.0&#8211;165.0)</td><td align="left" colspan="1" rowspan="1">150.0 (135.0&#8211;165.0)</td><td align="left" colspan="1" rowspan="1">0.38</td><td align="left" colspan="1" rowspan="1">150.0 (135.0&#8211;165.0)</td><td align="left" colspan="1" rowspan="1">0.17</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">HI</italic> hemorrhagic infarction, <italic toggle="yes">IQR</italic> inter-quartile range, <italic toggle="yes">p</italic> p value, <bold>*</bold>Statistically significant at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05.</p></table-wrap-foot></table-wrap>
</p><p id="Par62">We evaluated the relative contribution of the different variables to different subtypes of HT. We found that in univariate analysis, some factors had statistically significant predictive values of HI type 1 as follows: female gender (P-value 0.02), older age at presentation (P-value 0.03), baseline NIHSS on admission (P-value&#8201;&lt;&#8201;0.001), anterior-circulation stroke (P-value&#8201;&lt;&#8201;0.001), cardioembolic stroke (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), atrial fibrillation (P-value&#8201;&lt;&#8201;0.001), a stroke of undetermined aetiology (<italic toggle="yes">P</italic>&#8201;=&#8201;0.018), and large-vessel stroke (<italic toggle="yes">P</italic>&#8201;=&#8201;0.02). However, a multivariate regression model revealed that baseline NIHSS score (odds ratio [OR], 1.20; 95% CI, 1.18 to 1.21; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), anterior-circulation stroke (OR, 11.04; 95% CI, 9.81 to 12.70; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), and cardio-embolic stroke (OR, 1.69; 95%, CI, 1.62 to 1.76; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), independently predict HI type1, as shown in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>.</p><p id="Par63">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Univariate and multivariate logistic regression analysis of the characters and risk factors of patients with HI type1 (<italic toggle="yes">n</italic>&#8201;=&#8201;73).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th><th align="left" colspan="1" rowspan="1">Univariate, OR (LL&#8211;UL 95% C.I)</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" colspan="1" rowspan="1"><sup>#</sup>Multivariate, OR (LL&#8211;UL 95% C.I)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Females</td><td char="." align="char" colspan="1" rowspan="1">0.02<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">0.71* (0.67&#8211;0.76)</td><td char="." align="char" colspan="1" rowspan="1">0.093</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age at time of presentation</td><td char="." align="char" colspan="1" rowspan="1">0.03<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.02* (1.019&#8211;1.026)</td><td char="." align="char" colspan="1" rowspan="1">0.072</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Lesion location (anterior circulation)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.84* (1.70&#8211;2.00)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">11.04<sup>*</sup> (9.81&#8211;12.70)</td></tr><tr><td align="left" colspan="1" rowspan="1">NIHSS at time of admission</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.23* (1.22&#8211;1.54)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.196*(1.178&#8211;1.209)</td></tr><tr><td align="left" colspan="1" rowspan="1">Admission hyperglycemia</td><td char="." align="char" colspan="1" rowspan="1">0.32</td><td char="." align="char" colspan="1" rowspan="1">1.04 (0.97&#8211;1.11)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Door to needle time (min)</td><td char="." align="char" colspan="1" rowspan="1">0.388</td><td char="." align="char" colspan="1" rowspan="1">1.002 (0.997&#8211;1.008)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Time of receiving IV rtPA from stroke onset</td><td char="." align="char" colspan="1" rowspan="1">0.514</td><td char="." align="char" colspan="1" rowspan="1">0.998 (0.989&#8211;1.007)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hyperlipidemia</td><td char="." align="char" colspan="1" rowspan="1">0.617</td><td char="." align="char" colspan="1" rowspan="1">1.152 (0.627&#8211;2.474)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes mellitus</td><td char="." align="char" colspan="1" rowspan="1">0.534</td><td char="." align="char" colspan="1" rowspan="1">0.982 (0.469&#8211;2.100)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td char="." align="char" colspan="1" rowspan="1">0.471</td><td char="." align="char" colspan="1" rowspan="1">1.087 (0.509&#8211;2.318)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Previous TIA</td><td char="." align="char" colspan="1" rowspan="1">0.513</td><td char="." align="char" colspan="1" rowspan="1">0.812 (0.669&#8211;1.817)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">8.314* (3.127&#8211;21.147)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.689<sup>*</sup> (1.617&#8211;1.761)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ischemic heart disease</td><td char="." align="char" colspan="1" rowspan="1">0.317</td><td char="." align="char" colspan="1" rowspan="1">0.626 (0.147&#8211;1.950)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Large artery atherosclerosis</td><td char="." align="char" colspan="1" rowspan="1">0.02<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">2.028* (1.401&#8211;5.039)</td><td char="." align="char" colspan="1" rowspan="1">0.072</td><td char="." align="char" colspan="1" rowspan="1">7.657 (0.867&#8211;9.341)</td></tr><tr><td align="left" colspan="1" rowspan="1">Cardio -embolism</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">8.314* (3.128&#8211;20.788)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.689<sup>*</sup> (1.617&#8211;1.761)</td></tr><tr><td align="left" colspan="1" rowspan="1">Small artery occlusion</td><td char="." align="char" colspan="1" rowspan="1">0.421</td><td char="." align="char" colspan="1" rowspan="1">0.787 (0.412&#8211;1.060)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Stroke of undetermined etiology</td><td char="." align="char" colspan="1" rowspan="1">0.018<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">0.922 (0.862&#8211;0.986)</td><td char="." align="char" colspan="1" rowspan="1">0.436</td><td char="." align="char" colspan="1" rowspan="1">2.531 (0.354&#8211;6.247)</td></tr><tr><td align="left" colspan="1" rowspan="1">Temperature on admission</td><td char="." align="char" colspan="1" rowspan="1">0.124</td><td char="." align="char" colspan="1" rowspan="1">0.848 (0.841&#8211;1.247)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cholesterol level on admission</td><td char="." align="char" colspan="1" rowspan="1">0.512</td><td char="." align="char" colspan="1" rowspan="1">1.213 (0.714&#8211;2.354)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean value of two points evaluation of BP within 24&#160;h of symptoms onset</td><td char="." align="char" colspan="1" rowspan="1">0.431</td><td char="." align="char" colspan="1" rowspan="1">1.026 (0.514&#8211;2.417)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">OR</italic> odd&#8217;s ratio, <italic toggle="yes">HI</italic> hemorrhagic infarction, <italic toggle="yes">C.I</italic> confidence interval, <italic toggle="yes">LL</italic> lower limit, <italic toggle="yes">UL</italic> upper limit, <italic toggle="yes">CAD</italic> coronary artery disease.</p><p><sup>#</sup>All variables with <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 was included in the multivariate. *Statistically significant at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05.</p></table-wrap-foot></table-wrap>
</p><p id="Par64">We also found that in univariate analysis, some factors had statistically significant predictive value of HI type 2 as follows: older age at presentation (P-value 0.08), baseline NIHSS on admission (P-value&#8201;&lt;&#8201;0.001), anterior-circulation stroke (P-value&#8201;&lt;&#8201;0.001), cardioembolic stroke (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), atrial fibrillation (P-value&#8201;&lt;&#8201;0.001). However, a multivariate regression model revealed that baseline NIHSS score (odds ratio [OR], 1.30; 95% CI, 1.28 to 1.32; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), anterior-circulation stroke (OR, 11.89; 95% CI, 9.79 to 14.44; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) cardio-embolic stroke (OR, 1.59; 95%, CI, 1.42 to 1.86; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), independently predict HI type2, as shown in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>.</p><p id="Par65">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Univariate and multivariate logistic regression analysis of the characters and risk factors of patients with HI type2 (<italic toggle="yes">n</italic>&#8201;=&#8201;54).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th><th align="left" colspan="1" rowspan="1">Univariate, OR (LL&#8211;UL 95% C.I)</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" colspan="1" rowspan="1"><sup>#</sup>Multivariate, OR (LL&#8211;UL 95% C.I)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Females</td><td char="." align="char" colspan="1" rowspan="1">0.222</td><td char="." align="char" colspan="1" rowspan="1">1.049 (0.972&#8211;1.131)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age at time of presentation</td><td char="." align="char" colspan="1" rowspan="1">0.08</td><td char="." align="char" colspan="1" rowspan="1">0.922 (0.818&#8211;1.026)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Lesion location (anterior circulation)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">0.660* (0.604&#8211;0.720)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">11.889<sup>*</sup> (9.79&#8211;14.44)</td></tr><tr><td align="left" colspan="1" rowspan="1">NIHSS at time of admission</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.224* (1.213&#8211;1.235)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.302* (1.283&#8211;1.322)</td></tr><tr><td align="left" colspan="1" rowspan="1">Admission hyperglycemia</td><td char="." align="char" colspan="1" rowspan="1">0.07</td><td char="." align="char" colspan="1" rowspan="1">1.04 (0.97&#8211;1.11)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Door to needle time (min)</td><td char="." align="char" colspan="1" rowspan="1">0.066</td><td char="." align="char" colspan="1" rowspan="1">1.006 (1.000&#8211;1.012)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Time of receiving IV rtPA from stroke onset</td><td char="." align="char" colspan="1" rowspan="1">0.321</td><td char="." align="char" colspan="1" rowspan="1">0.814 (0.725&#8211;1.272)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hyperlipidemia</td><td char="." align="char" colspan="1" rowspan="1">0.537</td><td char="." align="char" colspan="1" rowspan="1">1.272 (0.717&#8211;2.574)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes mellitus</td><td char="." align="char" colspan="1" rowspan="1">0.334</td><td char="." align="char" colspan="1" rowspan="1">0.782 (0.569&#8211;2.230)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td char="." align="char" colspan="1" rowspan="1">0.357</td><td char="." align="char" colspan="1" rowspan="1">1.041 (0.609&#8211;2.618)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Previous TIA</td><td char="." align="char" colspan="1" rowspan="1">0.413</td><td char="." align="char" colspan="1" rowspan="1">0.812 (0.669&#8211;1.817)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">8.314* (3.127&#8211;21.147)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.689<sup>*</sup> (1.617&#8211;1.761)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ischemic heart disease</td><td char="." align="char" colspan="1" rowspan="1">0.137</td><td char="." align="char" colspan="1" rowspan="1">0.475 (0.347&#8211;1.550)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Admission hyperglycemia</td><td char="." align="char" colspan="1" rowspan="1">0.09</td><td char="." align="char" colspan="1" rowspan="1">1.418 (0.837&#8211;2.261)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Large artery atherosclerosis</td><td char="." align="char" colspan="1" rowspan="1">0.08</td><td char="." align="char" colspan="1" rowspan="1">1.528 (0.947&#8211;2.471)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cardio -embolism</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">8.114* (3.158&#8211;18.988)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.589<sup>*</sup> (1.417&#8211;1.861)</td></tr><tr><td align="left" colspan="1" rowspan="1">Small artery occlusion</td><td char="." align="char" colspan="1" rowspan="1">0.068</td><td char="." align="char" colspan="1" rowspan="1">0.922 (0.862&#8211;1.346)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Stroke of undetermined etiology</td><td char="." align="char" colspan="1" rowspan="1">0.068</td><td char="." align="char" colspan="1" rowspan="1">0.942 (0.64&#8211;1.56)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Temperature on admission</td><td char="." align="char" colspan="1" rowspan="1">0.113</td><td char="." align="char" colspan="1" rowspan="1">0.782 (0.912&#8211;1.357)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cholesterol level on admission</td><td char="." align="char" colspan="1" rowspan="1">0.411</td><td char="." align="char" colspan="1" rowspan="1">1.312 (0.824&#8211;2.244)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean value of two points evaluation of BP within 24&#160;h of symptoms onset</td><td char="." align="char" colspan="1" rowspan="1">0.451</td><td char="." align="char" colspan="1" rowspan="1">1.014 (0.614&#8211;2.357)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">OR</italic> odd&#8217;s ratio, <italic toggle="yes">HI</italic> hemorrhagic infarction, <italic toggle="yes">C.I</italic> confidence interval, <italic toggle="yes">LL</italic> lower limit, <italic toggle="yes">UL</italic> upper limit, <italic toggle="yes">CAD</italic> coronary artery disease.</p><p><sup>#</sup>All variables with <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 was included in the multivariate. *Statistically significant at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05. </p></table-wrap-foot></table-wrap>
</p><p id="Par66">Patients with PH type 1 and type 2 had statistically significant higher baseline NIHSS with P-values&#8201;&lt;&#8201;0.001&amp; &lt;0.001, respectively, as shown in Table&#160;<xref rid="Tab5" ref-type="table">5</xref>.</p><p id="Par67">
<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Patients&#8217; baseline characters in parenchymal hematoma (PH) type1 and type2.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Demographic data</th><th align="left" colspan="1" rowspan="1">(Non-HT group), <italic toggle="yes">N</italic>&#8201;=&#8201;464</th><th align="left" colspan="1" rowspan="1">Parenchymal hematoma 1, <italic toggle="yes">N</italic>&#8201;=&#8201;14</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th><th align="left" colspan="1" rowspan="1">Parenchymal hematoma 2, <italic toggle="yes">N</italic>&#8201;=&#8201;11</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Gender, no, (percentage)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male, no, (percentage)</td><td align="left" colspan="1" rowspan="1">288.0 (62.1%)</td><td align="left" colspan="1" rowspan="1">9.0 (64.3%)</td><td align="left" colspan="1" rowspan="1">0.87</td><td align="left" colspan="1" rowspan="1">8.0 (72.7%)</td><td align="left" colspan="1" rowspan="1">0.47</td></tr><tr><td align="left" colspan="1" rowspan="1">Age at time of presentation, median (IQR)</td><td align="left" colspan="1" rowspan="1">61.0 (58.0&#8211;66.0)</td><td align="left" colspan="1" rowspan="1">59.0 (59.0&#8211;65.0)</td><td align="left" colspan="1" rowspan="1">0.52</td><td align="left" colspan="1" rowspan="1">59.0 (58.0&#8211;70.0)</td><td align="left" colspan="1" rowspan="1">0.40</td></tr><tr><td align="left" colspan="6" rowspan="1">Location of infarction, no, (percentage)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Anterior circulation, no, (percentage)</td><td align="left" colspan="1" rowspan="1">320.0 (69%)</td><td align="left" colspan="1" rowspan="1">11.0 (78.6%)</td><td align="left" colspan="1" rowspan="1">0.44</td><td align="left" colspan="1" rowspan="1">9.0 (81.8%)</td><td align="left" colspan="1" rowspan="1">0.36</td></tr><tr><td align="left" colspan="1" rowspan="1">NIHSS at time of admission, median (IQR)</td><td align="left" colspan="1" rowspan="1">10 (7.3&#8211;17.0)</td><td align="left" colspan="1" rowspan="1">18.0 (15.0&#8211;20.0)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td align="left" colspan="1" rowspan="1">17.0 (14.0&#8211;20.0)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Door to needle time (min.), median (IQR)</td><td align="left" colspan="1" rowspan="1">60.0 (55.0&#8211;66.0)</td><td align="left" colspan="1" rowspan="1">55.0 (50.0&#8211;67.0)</td><td align="left" colspan="1" rowspan="1">0.50</td><td align="left" colspan="1" rowspan="1">59.0 (50.0&#8211;69.0)</td><td align="left" colspan="1" rowspan="1">0.51</td></tr><tr><td align="left" colspan="1" rowspan="1">Time of receiving IV rtPA from stroke onset (min.), median (IQR)</td><td align="left" colspan="1" rowspan="1">174.0 (163.0&#8211;200.0)</td><td align="left" colspan="1" rowspan="1">175.0 (155.0-200.0)</td><td align="left" colspan="1" rowspan="1">0.28</td><td align="left" colspan="1" rowspan="1">175.0 (155.0-200.0)</td><td align="left" colspan="1" rowspan="1">0.63</td></tr><tr><td align="left" colspan="6" rowspan="1">Patients on antiplatelets before stroke</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Aspirin and clopidogrel</td><td align="left" colspan="1" rowspan="1">120.0 (25.9%)</td><td align="left" colspan="1" rowspan="1">4.0 (28.6%)</td><td align="left" colspan="1" rowspan="1">0.82</td><td align="left" colspan="1" rowspan="1">2.0 (18.2%)</td><td align="left" colspan="1" rowspan="1">0.56</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Aspirin</td><td align="left" colspan="1" rowspan="1">114.0 (24.6%)</td><td align="left" colspan="1" rowspan="1">4.0 (28.6%)</td><td align="left" colspan="1" rowspan="1">0.69</td><td align="left" colspan="1" rowspan="1">3.0 (27.3%)</td><td align="left" colspan="1" rowspan="1">0.84</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Clopidogrel</td><td align="left" colspan="1" rowspan="1">90.0 (19.4%)</td><td align="left" colspan="1" rowspan="1">2.0 (14.3%)</td><td align="left" colspan="1" rowspan="1">0.63</td><td align="left" colspan="1" rowspan="1">2.0 (18.2%)</td><td align="left" colspan="1" rowspan="1">0.52</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Ticagrelor</td><td align="left" colspan="1" rowspan="1">15.0 (3.2%)</td><td align="left" colspan="1" rowspan="1">1.0 (7.1%)</td><td align="left" colspan="1" rowspan="1">0.44</td><td align="left" colspan="1" rowspan="1">1.0 (9.1%)</td><td align="left" colspan="1" rowspan="1">0.30</td></tr><tr><td align="left" colspan="6" rowspan="1">Patients on anticoagulants before stroke</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Warfarin</td><td align="left" colspan="1" rowspan="1">18.0 (3.9%)</td><td align="left" colspan="1" rowspan="1">1.0 (7.1%)</td><td align="left" colspan="1" rowspan="1">0.54</td><td align="left" colspan="1" rowspan="1">1.0 (9.1%)</td><td align="left" colspan="1" rowspan="1">0.38</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Rivaroxaban</td><td align="left" colspan="1" rowspan="1">14.0 (3.0%)</td><td align="left" colspan="1" rowspan="1">1.0 (7.1%)</td><td align="left" colspan="1" rowspan="1">0.38</td><td align="left" colspan="1" rowspan="1">1.0 (9.1%)</td><td align="left" colspan="1" rowspan="1">0.26</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Apixaban</td><td align="left" colspan="1" rowspan="1">10.0 (2.2%)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (9.1%)</td><td align="left" colspan="1" rowspan="1">0.13</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">IQR</italic> inter-quartile range, <italic toggle="yes">p</italic> p value, *Statistically significant at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05, <italic toggle="yes">PH</italic> parenchymal hematoma.</p></table-wrap-foot></table-wrap>
</p><p id="Par68">Patients with PH type1 and 2 had a statistically significant higher percentage of atrial fibrillation and cardio-embolic stroke with a P-value 0.03&amp; 0.04&amp; &lt; 0.001&amp; &lt;0.001, respectively as shown in Table&#160;<xref rid="Tab6" ref-type="table">6</xref>.</p><p id="Par69">
<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Comparison between the non-HT patients and PH patients&#8217; risk factors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Risk factor, no, (percentage)</th><th align="left" colspan="1" rowspan="1">(Non-HT group), <italic toggle="yes">N</italic>&#8201;=&#8201;464</th><th align="left" colspan="1" rowspan="1">Parenchymal hematoma 1, <italic toggle="yes">N</italic>&#8201;=&#8201;14</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th><th align="left" colspan="1" rowspan="1">Parenchymal hematoma 2, <italic toggle="yes">N</italic>&#8201;=&#8201;11</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Hyperlipidemia</td><td align="left" colspan="1" rowspan="1">156.0 (33.6%)</td><td align="left" colspan="1" rowspan="1">4.0 (28.6%)</td><td align="left" colspan="1" rowspan="1">0.70</td><td align="left" colspan="1" rowspan="1">3.0 (27.3%)</td><td align="left" colspan="1" rowspan="1">0.66</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes mellitus</td><td align="left" colspan="1" rowspan="1">164.0 (35.3%)</td><td align="left" colspan="1" rowspan="1">5.0 (35.7%)</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">4.0 (28.6%)</td><td align="left" colspan="1" rowspan="1">0.94</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td align="left" colspan="1" rowspan="1">288.0 (62.1%)</td><td align="left" colspan="1" rowspan="1">9.0 (64.3%)</td><td align="left" colspan="1" rowspan="1">0.87</td><td align="left" colspan="1" rowspan="1">7.0 (63.6%)</td><td align="left" colspan="1" rowspan="1">0.92</td></tr><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation</td><td align="left" colspan="1" rowspan="1">67.0 (14.4%)</td><td align="left" colspan="1" rowspan="1">5.0 (35.7%)</td><td align="left" colspan="1" rowspan="1">0.03<sup>*</sup></td><td align="left" colspan="1" rowspan="1">4.0 (28.6%)</td><td align="left" colspan="1" rowspan="1">0.04<sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Ischemic heart disease</td><td align="left" colspan="1" rowspan="1">57.0 (12.3%)</td><td align="left" colspan="1" rowspan="1">2.0 (14.3%)</td><td align="left" colspan="1" rowspan="1">0.82</td><td align="left" colspan="1" rowspan="1">1.0 (9.1%)</td><td align="left" colspan="1" rowspan="1">0.75</td></tr><tr><td align="left" colspan="1" rowspan="1">Admission hyperglycemia</td><td align="left" colspan="1" rowspan="1">140.0 (30.2%)</td><td align="left" colspan="1" rowspan="1">5.0 (35.7%)</td><td align="left" colspan="1" rowspan="1">0.66</td><td align="left" colspan="1" rowspan="1">4.0 (28.6%)</td><td align="left" colspan="1" rowspan="1">0.66</td></tr><tr><td align="left" colspan="1" rowspan="1">Previous TIA</td><td align="left" colspan="1" rowspan="1">131.0 (28.2%)</td><td align="left" colspan="1" rowspan="1">4.0 (28.6%)</td><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">3.0 (27.3%)</td><td align="left" colspan="1" rowspan="1">0.94</td></tr><tr><td align="left" colspan="6" rowspan="1">Etiology, no, (percentage)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Large artery atherosclerosis</td><td align="left" colspan="1" rowspan="1">68.0 (14.7%)</td><td align="left" colspan="1" rowspan="1">4.0 (28.6%)</td><td align="left" colspan="1" rowspan="1">0.15</td><td align="left" colspan="1" rowspan="1">3.0 (27.3%)</td><td align="left" colspan="1" rowspan="1">0.25</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Cardio-embolism</td><td align="left" colspan="1" rowspan="1">55.0 (11.9%)</td><td align="left" colspan="1" rowspan="1">6.0 (42.9%)</td><td align="left" colspan="1" rowspan="1">0.001<sup>*</sup></td><td align="left" colspan="1" rowspan="1">5.0 (45.5%)</td><td align="left" colspan="1" rowspan="1">0.001<sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Small artery occlusion</td><td align="left" colspan="1" rowspan="1">152.0 (32.8%)</td><td align="left" colspan="1" rowspan="1">2.0 (14.3%)</td><td align="left" colspan="1" rowspan="1">0.15</td><td align="left" colspan="1" rowspan="1">1.0 (9.1%)</td><td align="left" colspan="1" rowspan="1">0.10</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Stroke of undetermined etiology</td><td align="left" colspan="1" rowspan="1">136.0 (29.3%)</td><td align="left" colspan="1" rowspan="1">6.0 (42.9%)</td><td align="left" colspan="1" rowspan="1">0.27</td><td align="left" colspan="1" rowspan="1">5.0 (45.5%)</td><td align="left" colspan="1" rowspan="1">0.25</td></tr><tr><td align="left" colspan="6" rowspan="1">Co-morbid conditions on admission</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Temperature on admission, &#186;C, median (IQR)</td><td align="left" colspan="1" rowspan="1">37.4 (37.2&#8211;37.8)</td><td align="left" colspan="1" rowspan="1">37.7 (37.3&#8211;38.0)</td><td align="left" colspan="1" rowspan="1">0.18</td><td align="left" colspan="1" rowspan="1">37.7 (37.3&#8211;38.0)</td><td align="left" colspan="1" rowspan="1">0.14</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Cholesterol level on admission, mg/dL, median (IQR)</td><td align="left" colspan="1" rowspan="1">188.0 (181.0&#8211;237.0)</td><td align="left" colspan="1" rowspan="1">201.0 (192.0&#8211;242.0)</td><td align="left" colspan="1" rowspan="1">0.21</td><td align="left" colspan="1" rowspan="1">193.0 (190.0&#8211;240.0)</td><td align="left" colspan="1" rowspan="1">0.24</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean value of two points evaluation of BP within 24&#160;h of symptoms onset, mmHg, median (IQR)</td><td align="left" colspan="1" rowspan="1">145.0 (130.0&#8211;165.0)</td><td align="left" colspan="1" rowspan="1">155.0 (135.0&#8211;165.0)</td><td align="left" colspan="1" rowspan="1">0.27</td><td align="left" colspan="1" rowspan="1">160.0 (140.0&#8211;165.0)</td><td align="left" colspan="1" rowspan="1">0.14</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">p</italic> p value, <italic toggle="yes">PH</italic> parenchymal hematoma, <italic toggle="yes">IQR</italic> inter-quartile range. *Statistically significant at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05.</p></table-wrap-foot></table-wrap>
</p><p id="Par70">In addition, we found that, in univariate analysis, some factors had statistically significant predictive values of PH type1 as follows: older age at presentation (P-value 0.007), baseline NIHSS on admission (P-value&#8201;&lt;&#8201;0.001), cardioembolic stroke (P-value&#8201;&lt;&#8201;0.001), atrial fibrillation (P-value&#8201;&lt;&#8201;0.001). However, a multivariate regression model revealed that baseline NIHSS score (odds ratio [OR], 1.40; 95% CI, 1.55 to 1.81; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), older age (OR, 1.31; 95% CI, 1.25 to 1.91; P-value 0.02) cardio-embolic stroke (OR, 1.429; 95% CI, 1.517 to 1.941; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), independently predict PH type1, as shown in Table&#160;<xref rid="Tab7" ref-type="table">7</xref>.</p><p id="Par71">
<table-wrap id="Tab7" position="float" orientation="portrait"><label>Table 7</label><caption><p>Univariate and multivariate logistic regression analysis of the characters and risk factors of patients with PH 1 (<italic toggle="yes">n</italic>&#8201;=&#8201;14).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th><th align="left" colspan="1" rowspan="1">Univariate, OR (LL&#8211;UL 95% C.I)</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" colspan="1" rowspan="1"><sup>#</sup>Multivariate, OR (LL&#8211;UL 95% C.I)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Females</td><td char="." align="char" colspan="1" rowspan="1">0.220</td><td char="." align="char" colspan="1" rowspan="1">1.093 (0.949&#8211;1.259)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age at time of presentation</td><td char="." align="char" colspan="1" rowspan="1">0.007<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.414* (1.279&#8211;1.729)</td><td char="." align="char" colspan="1" rowspan="1"><bold>0.02</bold>*</td><td char="." align="char" colspan="1" rowspan="1">1.312* (1.245&#8211;1.912)</td></tr><tr><td align="left" colspan="1" rowspan="1">Lesion location (anterior circulation)</td><td char="." align="char" colspan="1" rowspan="1">0.09</td><td char="." align="char" colspan="1" rowspan="1">1.062 (0.871&#8211;1.314)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">NIHSS at time of admission</td><td char="." align="char" colspan="1" rowspan="1">&lt; 0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.304* (1.279&#8211;1.329)</td><td char="." align="char" colspan="1" rowspan="1">&lt; 0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.402* (1.545&#8211;1.812)</td></tr><tr><td align="left" colspan="1" rowspan="1">Admission hyperglycemia</td><td char="." align="char" colspan="1" rowspan="1">0.07</td><td char="." align="char" colspan="1" rowspan="1">1.04 (0.97&#8211;1.11)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Door to needle time (min)</td><td char="." align="char" colspan="1" rowspan="1">0.066</td><td char="." align="char" colspan="1" rowspan="1">1.006 (1.000&#8211;1.012)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Time of receiving IV rtPA from stroke onset</td><td char="." align="char" colspan="1" rowspan="1">0.321</td><td char="." align="char" colspan="1" rowspan="1">0.814 (0.725&#8211;1.272)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hyperlipidemia</td><td char="." align="char" colspan="1" rowspan="1">0.327</td><td char="." align="char" colspan="1" rowspan="1">1.482 (0.817&#8211;1.974)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes mellitus</td><td char="." align="char" colspan="1" rowspan="1">0.393</td><td char="." align="char" colspan="1" rowspan="1">1.063 (0.924&#8211;1.224)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td char="." align="char" colspan="1" rowspan="1">0.174</td><td char="." align="char" colspan="1" rowspan="1">1.021 (0.727&#8211;1.938)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Previous TIA</td><td char="." align="char" colspan="1" rowspan="1">0.641</td><td char="." align="char" colspan="1" rowspan="1">0.712 (0.642&#8211;1.719)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation</td><td char="." align="char" colspan="1" rowspan="1">&lt; 0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">9.114* (4.137&#8211;22.167)</td><td char="." align="char" colspan="1" rowspan="1">&lt; 0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.689<sup>*</sup> (1.617&#8211;1.761)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ischemic heart disease</td><td char="." align="char" colspan="1" rowspan="1">0.137</td><td char="." align="char" colspan="1" rowspan="1">0.475 (0.347&#8211;1.550)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Admission hyperglycemia</td><td char="." align="char" colspan="1" rowspan="1">0.21</td><td char="." align="char" colspan="1" rowspan="1">1.128 (0.847&#8211;1.971)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Large artery atherosclerosis</td><td char="." align="char" colspan="1" rowspan="1">0.13</td><td char="." align="char" colspan="1" rowspan="1">1.438 (0.947&#8211;2.171)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cardio -embolism</td><td char="." align="char" colspan="1" rowspan="1">&lt; 0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">8.834* (3.128&#8211;17.968)</td><td char="." align="char" colspan="1" rowspan="1">&lt; 0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.429<sup>*</sup> (1.517&#8211;1.941)</td></tr><tr><td align="left" colspan="1" rowspan="1">Small artery occlusion</td><td char="." align="char" colspan="1" rowspan="1">0.128</td><td char="." align="char" colspan="1" rowspan="1">0.712 (0.962&#8211;1.646)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Temperature on admission</td><td char="." align="char" colspan="1" rowspan="1">0.183</td><td char="." align="char" colspan="1" rowspan="1">0.817 (0.911&#8211;1.129)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cholesterol level on admission</td><td char="." align="char" colspan="1" rowspan="1">0.462</td><td char="." align="char" colspan="1" rowspan="1">1.343 (0.714&#8211;2.184)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean value of two points evaluation of BP within 24&#160;h of symptoms onset</td><td char="." align="char" colspan="1" rowspan="1">0.542</td><td char="." align="char" colspan="1" rowspan="1">1.286 (0.753&#8211;2.713)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">OR</italic> odd&#8217;s ratio, <italic toggle="yes">PH</italic> parenchymal hematoma, <italic toggle="yes">C.I</italic> confidence interval, <italic toggle="yes">LL</italic> lower limit, <italic toggle="yes">UL</italic> upper limit, <italic toggle="yes">CAD</italic> coronary artery disease.</p><p><sup>#</sup>All variables with <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 was included in the multivariate. *Statistically significant at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05.</p></table-wrap-foot></table-wrap>
</p><p id="Par72">We also found that in univariate analysis, some factors had statistically significant predictive values of PH type2 as follows: baseline NIHSS on admission (P-value&#8201;&lt;&#8201;0.001), cardioembolic stroke (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), and atrial fibrillation (P-value&#8201;&lt;&#8201;0.001). However, a multivariate regression model revealed that baseline NIHSS score (odds ratio [OR], 1.312; 95% CI, 1.645 to 1.932; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), cardio-embolic stroke (OR, 1.329; 95%, CI, 1.417 to 1.951; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), independently predict PH type2, as shown in Table&#160;<xref rid="Tab8" ref-type="table">8</xref>.</p><p id="Par73">
<table-wrap id="Tab8" position="float" orientation="portrait"><label>Table 8</label><caption><p>Univariate and multivariate logistic regression analysis of the characters and risk factors of patients with PH 2 (<italic toggle="yes">n</italic>&#8201;=&#8201;11).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th><th align="left" colspan="1" rowspan="1">Univariate, OR (LL&#8211;UL 95% C. I)</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" colspan="1" rowspan="1"><sup>#</sup>Multivariate, OR (LL&#8211;UL 95%C.I)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Females</td><td char="." align="char" colspan="1" rowspan="1">0.310</td><td char="." align="char" colspan="1" rowspan="1">1.083 (0.849&#8211;1.314)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age at time of presentation</td><td char="." align="char" colspan="1" rowspan="1">0.08</td><td char="." align="char" colspan="1" rowspan="1">1.172 (1.119&#8211;1.529)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Lesion location (anterior circulation)</td><td char="." align="char" colspan="1" rowspan="1">0.07</td><td char="." align="char" colspan="1" rowspan="1">1.112 (0.807&#8211;1.427)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">NIHSS at time of admission</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.134* (1.242&#8211;1.412)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.312* (1.645&#8211;1.932)</td></tr><tr><td align="left" colspan="1" rowspan="1">Admission hyperglycemia</td><td char="." align="char" colspan="1" rowspan="1">0.112</td><td char="." align="char" colspan="1" rowspan="1">1.09 (0.95&#8211;1.21)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Door to needle time (min)</td><td char="." align="char" colspan="1" rowspan="1">0.086</td><td char="." align="char" colspan="1" rowspan="1">1.008 (0.917&#8211;1.132)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Time of receiving IV rtPA from stroke onset</td><td char="." align="char" colspan="1" rowspan="1">0.211</td><td char="." align="char" colspan="1" rowspan="1">0.874 (0.716&#8211;1.322)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hyperlipidemia</td><td char="." align="char" colspan="1" rowspan="1">0.127</td><td char="." align="char" colspan="1" rowspan="1">1.322 (0.717&#8211;1.734)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes mellitus</td><td char="." align="char" colspan="1" rowspan="1">0.273</td><td char="." align="char" colspan="1" rowspan="1">1.043 (0.914&#8211;1.324)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td char="." align="char" colspan="1" rowspan="1">0.244</td><td char="." align="char" colspan="1" rowspan="1">1.051 (0.711&#8211;1.728)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Previous TIA</td><td char="." align="char" colspan="1" rowspan="1">0.571</td><td char="." align="char" colspan="1" rowspan="1">0.781 (0.742&#8211;1.763)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">7.164* (3.437&#8211;20.785)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.649<sup>*</sup> (1.817&#8211;1.981)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ischemic heart disease</td><td char="." align="char" colspan="1" rowspan="1">0.149</td><td char="." align="char" colspan="1" rowspan="1">0.412 (0.317&#8211;1.452)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Admission hyperglycemia</td><td char="." align="char" colspan="1" rowspan="1">0.208</td><td char="." align="char" colspan="1" rowspan="1">1.168 (0.811&#8211;1.751)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Large artery atherosclerosis</td><td char="." align="char" colspan="1" rowspan="1">0.152</td><td char="." align="char" colspan="1" rowspan="1">1.511 (0.913&#8211;2.153)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cardio -embolism</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">8.114* (5.128&#8211;14.958)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001<sup>*</sup></td><td char="." align="char" colspan="1" rowspan="1">1.329<sup>*</sup> (1.417&#8211;1.951)</td></tr><tr><td align="left" colspan="1" rowspan="1">Small artery occlusion</td><td char="." align="char" colspan="1" rowspan="1">0.211</td><td char="." align="char" colspan="1" rowspan="1">0.752 (0.912&#8211;1.516)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Stroke of undetermined etiology</td><td char="." align="char" colspan="1" rowspan="1">0.261</td><td char="." align="char" colspan="1" rowspan="1">1.071 (0.934&#8211;1.219)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Temperature on admission</td><td char="." align="char" colspan="1" rowspan="1">0.197</td><td char="." align="char" colspan="1" rowspan="1">1.048 (0.934&#8211;1.318)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Cholesterol level on admission</td><td char="." align="char" colspan="1" rowspan="1">0.537</td><td char="." align="char" colspan="1" rowspan="1">1.353 (0.714&#8211;2.493)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Mean value of two points evaluation of BP within 24&#160;h of symptoms onset</td><td char="." align="char" colspan="1" rowspan="1">0.348</td><td char="." align="char" colspan="1" rowspan="1">1.173 (0.514&#8211;2.278)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">OR</italic> odd&#8217;s ratio, <italic toggle="yes">PH</italic> parenchymal hematoma, <italic toggle="yes">C.I</italic> confidence interval, <italic toggle="yes">LL</italic> lower limit, <italic toggle="yes">UL</italic> upper limit, <italic toggle="yes">CAD</italic> coronary artery disease.</p><p><sup>#</sup>All variables with <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 was included in the multivariate, *Statistically significant at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05. </p></table-wrap-foot></table-wrap>
</p><p id="Par74">Regarding the mortality among our patients, we found that 22 (14.5%) patients among those who experienced hemorrhagic transformation died during their hospital stay, of which one patient died due to recurrent ischemic stroke, one due to brain oedema, one due to seizures, seven due to haemorrhagic infarction, five due to pneumonia, two due to pulmonary embolism, three due to myocardial infarction, one due to acute renal failure, and one due to orolingual oedema, also 32 (6.9%) patients in the non-HT group patients died during their hospital stay of which three patients died due to recurrent stroke, three due to brain oedema, three due to seizures, eight due to pneumonia, four due to pulmonary embolism, seven due to myocardial infarction, three due to acute renal failure, and one due to orolingual oedema, (HR 2.38; 95% CI, 1.36&#8211;4.17; P-value&#8201;=&#8201;0.003) as shown in Table&#160;<xref rid="Tab9" ref-type="table">9</xref>.</p><p id="Par75">
<table-wrap id="Tab9" position="float" orientation="portrait"><label>Table 9</label><caption><p>Mortality rates and causes during hospital stay in HT and non-HT groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Death causes</th><th align="left" colspan="1" rowspan="1">(Non-HT group) <italic toggle="yes">N</italic>&#8201;=&#8201;464</th><th align="left" colspan="1" rowspan="1">(HT group) <italic toggle="yes">N</italic>&#8201;=&#8201;152</th><th align="left" colspan="1" rowspan="1">Hazard ratio (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">All causes of death</td><td char="." align="char" colspan="1" rowspan="1">32.0 (6.9%)</td><td char="." align="char" colspan="1" rowspan="1">22.0 (14.5%)</td><td align="left" rowspan="12" colspan="1">2.38 (1.36&#8211;4.17)</td><td align="left" rowspan="12" colspan="1">0.003*</td></tr><tr><td align="left" colspan="3" rowspan="1">Neurological mortality causes</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Recurrent ischemic stroke</td><td char="." align="char" colspan="1" rowspan="1">3.0 (0.6%)</td><td char="." align="char" colspan="1" rowspan="1">1.0 (0.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Brain edema</td><td char="." align="char" colspan="1" rowspan="1">3.0 (0.6%)</td><td char="." align="char" colspan="1" rowspan="1">1.0 (0.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hemorrhagic infarction</td><td char="." align="char" colspan="1" rowspan="1">0.0</td><td char="." align="char" colspan="1" rowspan="1">7.0 (8.6%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Seizures</td><td char="." align="char" colspan="1" rowspan="1">3.0 (0.6%)</td><td char="." align="char" colspan="1" rowspan="1">1.0 (0.7%)</td></tr><tr><td align="left" colspan="3" rowspan="1">Non-neurological mortality causes</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Pneumonia</td><td char="." align="char" colspan="1" rowspan="1">8.0 (1.7%)</td><td char="." align="char" colspan="1" rowspan="1">5.0 (3.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Pulmonary embolism</td><td char="." align="char" colspan="1" rowspan="1">4.0 (0.9%)</td><td char="." align="char" colspan="1" rowspan="1">2.0 (1.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Myocardial infarction</td><td char="." align="char" colspan="1" rowspan="1">7.0 (1.5%)</td><td char="." align="char" colspan="1" rowspan="1">3.0 (2.0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Acute renal failure</td><td char="." align="char" colspan="1" rowspan="1">3.0 (0.6%)</td><td char="." align="char" colspan="1" rowspan="1">1.0 (0.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Orolingual edema</td><td char="." align="char" colspan="1" rowspan="1">1.0 (0.2%)</td><td char="." align="char" colspan="1" rowspan="1">1.0 (0.7%)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CI</italic> confidence interval, <italic toggle="yes">p</italic> value, <italic toggle="yes">HT</italic> hemorrhagic transformation. *Statistically significant at <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p id="Par76">Although alteplase is the only FDA-approved treatment for acute stroke, it could lead to HT<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>, and the global prevalence of HT in patients treated with alteplase was 32%. In comparison, in East Asia, 35%, and in non-east Asia, 31%<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>; however, most studies evaluated the post-alteplase haemorrhagic transformation of brain infarction as a homogeneous entity and the factors that contributed to haemorrhagic infarction subtypes in the Arab population are poorly understood, so we conducted our study to be the first-ever multicentre prospective study that evaluated the predictors of each subtype of post-alteplase haemorrhagic infarction in the Middle East.</p><p id="Par77">Our study&#8217;s primary outcome was the HT1 as it was the commonest hemorrhagic transformation<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. while our secondary outcome included the other types of hemorrhagic transformation.</p><p id="Par78">In our study, 24.7% of the patients had a haemorrhagic transformation, and this agrees with the findings of Strbian et al. and Sun et al.<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>, who stated that up to 30% of AIS patients who were treated with tPA had haemorrhagic transformation. Most of the HT was asymptomatic, but in our study, 75 patients (12.2%) had symptomatic worsening due to HT.</p><p id="Par79">Our analysis showed that in the Arab population from Egypt and Saudi Arabia, gender and door-to-needle time (DTN) were not predictive factors of any HT subtypes in AIS patients treated with tPA; our findings agreed with Lansberg et al., Liu et al., Nisar et al., and Sun et al.<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref></sup>, who stated that gender, DTN did not predict haemorrhagic transformation in AIS patients treated with tPA, and disagreed with the findings of Chenna et al. and Xue et al.<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>, who found that DTN was an independent predictor of haemorrhagic transformation in AIS patients treated with tPA.</p><p id="Par80">Our finding that DTN time did not predict the haemorrhagic transformation in AIS patients may be attributed to the fact that in our HT group, the median time from onset to thrombolysis was 180&#160;min, which was shorter than the median time from onset to thrombolysis in the study of Chenna et al.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> which was 227&#160;min. The median DTN time in our patients was 55&#160;min shorter than the median DTN time in the study of Xue et al.<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>, which was 66&#160;min. It is recognized that the longer the time to thrombolysis, the higher the occurrence of the haemorrhagic transformation.</p><p id="Par81">Our study found that older age was not a predictor of HI type 1, HI type 2, and PH type 2. This disagreed with the results of Liu et al. and Sun et al.<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>, who found that age&#8201;&#8805;&#8201;68 and age&#8201;&#8805;&#8201;70, respectively, were predictors of haemorrhagic transformation in AIS patients treated with tPA. Also, our finding that age did not predict the haemorrhagic transformation in HI type 1, HI type 2, and PH type 2 patients can be attributed to the relatively younger mean age of our patients, which was 62 years, and that our study included patients aged younger than 75 years, unlike the mean ages in the study of Liu et al. and Sun et al.<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup> which were 67 years and 69 years and the two studies included patients aged up to 80 years. It is known that age&#8201;<italic toggle="yes">&gt;</italic>&#8201;75 years increases the risk of HT.</p><p id="Par82">We found that admission hyperthermia did not predict the haemorrhagic transformation in AIS patients, which disagreed partially with the findings of Leira et al.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, who found that high body temperature within the first 24&#160;h after ischemic stroke is a risk factor for HT in patients untreated with rtPA, this could be explained as Leira study included patients who did not receive alteplase and it is known that patients who received alteplase have different outcomes and complications than those who did not receive alteplase<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>.</p><p id="Par83">In addition, we found that hyperlipidaemia was not a predictor of haemorrhagic transformation in AIS patients, which agreed with the findings of Mart&#237;nez et al.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>, who found that total cholesterol level was not associated with increased risk of parenchymal haemorrhagic transformation.</p><p id="Par84">We also found that admission blood pressure could not predict the haemorrhagic transformation in AIS patients, which agreed with van den Berg et al.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>, who found that elevated systolic blood pressure was not associated with the risk of haemorrhagic transformation.</p><p id="Par85">Also, we found that higher baseline NIHSS was an independent predictor of all Haemorrhagic infarction subtypes. At the same time, anterior-circulation stroke was an independent predictor of HT types 1 and 2, which agreed with Chenna et al., Dornak et al., Sun et al., and Xue et al.<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>.</p><p id="Par86">Regarding the analysis of the relationship between different risk factors and the haemorrhagic transformation, we found that atrial fibrillation (AF) was an independent predictor of all haemorrhagic infarction subtypes; this agreed with the findings of Cronin et al., Tong et al., and Al-Khaled et al.<sup><xref ref-type="bibr" rid="CR34">34</xref>&#8211;<xref ref-type="bibr" rid="CR36">36</xref></sup> who found that atrial fibrillation, was related to the haemorrhagic transformation in AIS patients.</p><p id="Par87">Concerning the analysis of the relationship between different ischemic stroke aetiologies and the haemorrhagic transformation, we found that cardioembolic stroke was an independent predictor of all haemorrhagic infarction subtypes; this agreed with the findings of Liu et al. and Xue et al.<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>.</p><p id="Par88">In our study, we found a significantly higher hospital mortality rate in the HT group due to neurological and non-neurological complications compared to the non-HT group; this agreed with the findings of Kastrup et al.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, who found that HT increased post-stroke mortality.</p><p id="Par89">Although our results were encouraging, our study has some limitations. First, the prospective nature of our study led to a relatively small number of patients; second, the study had patients from two Middle Eastern countries; third, we did not include an indicator of white matter lesions burden in our analysis due to the unavailability of a specific MRI software program.</p><p id="Par90">Many aspects need thorough investigation in future studies, such as the assessment of the efficacy and safety of alteplase in patients aged 85 years and older as they have different demographics and risk factors<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> and identifying the predictors of different types of hemorrhagic transformation in different ethnicities to allow more generalization of the results and evaluating the impact of white matter hyperintensities burden on hemorrhagic transformation post-alteplase, in addition, we need to investigate the predictors of hemorrhagic transformation after alteplase in specific groups of ischemic stroke patients such as atrial fibrillation patients.</p></sec><sec id="Sec15" sec-type="conclusion"><title>Conclusion</title><p id="Par91">In AIS patients treated with alteplase in Egypt and Saudi Arabia, higher NIHSS, cardioembolic stroke and atrial fibrillation were independent predictors of all ECASS-based subtypes of hemorrhagic infarction; in addition, anterior-circulation stroke was an independent predictor of hemorrhagic infarction type 1 and 2, while older age was also an independent predictor of parenchymal hematoma type1.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AIS</term><def><p id="Par3">Acute ischemic stroke</p></def></def-item><def-item><term>ACS</term><def><p id="Par4">Anterior-circulation stroke</p></def></def-item><def-item><term>CNS</term><def><p id="Par5">Central nervous system</p></def></def-item><def-item><term>CT</term><def><p id="Par6">Computerized tomography</p></def></def-item><def-item><term>ECASS</term><def><p id="Par7">European cooperative acute stroke study</p></def></def-item><def-item><term>ECG</term><def><p id="Par8">Electrocardiogram</p></def></def-item><def-item><term>FDA</term><def><p id="Par9">Food and drug administration</p></def></def-item><def-item><term>HT</term><def><p id="Par10">Hemorrhagic transformation</p></def></def-item><def-item><term>INR</term><def><p id="Par11">International normalization ratio</p></def></def-item><def-item><term>IQR</term><def><p id="Par12">Inter quartile range</p></def></def-item><def-item><term>MRA</term><def><p id="Par13">Magnetic resonance angiography</p></def></def-item><def-item><term>MRI</term><def><p id="Par14">Magnetic resonance imaging</p></def></def-item><def-item><term>mRS</term><def><p id="Par15">Modified Rankin scale</p></def></def-item><def-item><term>NIHSS</term><def><p id="Par16">National institute of health stroke score</p></def></def-item><def-item><term>PCS</term><def><p id="Par17">Posterior-circulation stroke</p></def></def-item><def-item><term>TPA</term><def><p id="Par18">Recombinant tissue plasminogen activator</p></def></def-item><def-item><term>TIA</term><def><p id="Par19">Transient ischemic attack</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>Dr M.Z., Dr S.A., Dr M.K., Dr I.K., and Dr A.K. were the principal investigators who collected data; Dr A.S., Dr A.EL., Dr. M.A., Dr. T.Y., Dr. A.D., Dr. H.R., Dr. A.Eb. and Dr. O.A. shared in the study plan revision and supervision, Dr A.A. shared in the analysis of CT and MRI of the patients, while Dr M.Z. shared in data analysis and manuscript writing. Dr M.I., Dr S.A., Dr Ah. A., and Dr. A.I. prepared and analyzed the data needed for revision and prepared the authors&#8217; response to reviewers&#8217; comments. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The Science, Technology &amp; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated and analyzed during the current study are not publicly available due to the ethical regulations of our university, but are available from the corresponding author (Mohamed G. Zeinhom) on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par92">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethical review board</title><p id="Par93">This study protocol was reviewed and approved by the scientific research ethics committee at Kafr El-Sheikh University in Egypt, and the approval number was KFSIRB200-66. We obtained a written informed consent from all adults participating in this study. Our study did not include any vulnerable patient.</p></notes><notes id="FPar3"><title>Consent to participate</title><p id="Par96">Before inclusion in the study, formal written informed consent was obtained from the included patients.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Zeinhom, M. G., Elbassiouny, A., Mahmoud, A., Sherihan, M. &amp; Ahmed, R. Ticagrelor versus clopidogrel in acute large &#8211; vessel ischemic stroke: a randomized controlled single &#8211; blinded trial. <italic toggle="yes">CNS Drugs </italic><bold>450</bold> (0123456789). 10.1007/s40263-024-01080-5 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40263-024-01080-5</pub-id><pub-id pub-id-type="pmcid">PMC11026220</pub-id><pub-id pub-id-type="pmid">38619649</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Zeinhom, M. G. et al. Predictors of the unfavorable outcomes in acute ischemic stroke patients treated with alteplase, a multi &#8211; center randomized trial. <italic toggle="yes">Sci. Rep.</italic> 1&#8211;9. 10.1038/s41598-024-56067-5 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-024-56067-5</pub-id><pub-id pub-id-type="pmcid">PMC10933394</pub-id><pub-id pub-id-type="pmid">38472241</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strbian</surname><given-names>D</given-names></name><etal/></person-group><article-title>Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis</article-title><source>Neurology</source><year>2011</year><volume>77</volume><issue>4</issue><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182267b8c</pub-id><pub-id pub-id-type="pmid">21715707</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Strbian, D. et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. <italic toggle="yes">Neurology </italic><bold>77</bold> (4), 341&#8211;348 (2011). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://n.neurology.org/content/77/4/341.abstract">http://n.neurology.org/content/77/4/341.abstract</ext-link><pub-id pub-id-type="pmid">21715707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182267b8c</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Honig, A. et al. Hemorrhagic transformation in acute ischemic stroke: a quantitative systematic review. <italic toggle="yes">J. Clin. Med. </italic><bold>11</bold>(5) (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm11051162</pub-id><pub-id pub-id-type="pmcid">PMC8910828</pub-id><pub-id pub-id-type="pmid">35268253</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powers</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke A</article-title><source>Stroke</source><year>2019</year><volume>50</volume><fpage>344</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1161/STR.0000000000000211</pub-id><pub-id pub-id-type="pmid">30626290</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Powers, W. J. et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke A. <italic toggle="yes">Stroke </italic><bold>50</bold>, 344&#8211;418 (2019).<pub-id pub-id-type="pmid">30626290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.118.022606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spronk</surname><given-names>E</given-names></name><etal/></person-group><article-title>Hemorrhagic transformation in ischemic stroke and the role of inflammation</article-title><source>Front. Neurol.</source><year>2021</year><volume>12</volume><fpage>661955</fpage><pub-id pub-id-type="doi">10.3389/fneur.2021.661955</pub-id><pub-id pub-id-type="pmid">34054705</pub-id><pub-id pub-id-type="pmcid">PMC8160112</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Spronk, E. et al. Hemorrhagic transformation in ischemic stroke and the role of inflammation. <italic toggle="yes">Front. Neurol. </italic><bold>12</bold>, 661955 (2021).<pub-id pub-id-type="pmid">34054705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.661955</pub-id><pub-id pub-id-type="pmcid">PMC8160112</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritzel</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Aging alters the immunological response to ischemic stroke</article-title><source>Acta Neuropathol.</source><year>2018</year><volume>136</volume><issue>1</issue><fpage>89</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1007/s00401-018-1859-2</pub-id><pub-id pub-id-type="pmid">29752550</pub-id><pub-id pub-id-type="pmcid">PMC6015099</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ritzel, R. M. et al. Aging alters the immunological response to ischemic stroke. <italic toggle="yes">Acta Neuropathol. </italic><bold>136</bold> (1), 89&#8211;110 (2018).<pub-id pub-id-type="pmid">29752550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00401-018-1859-2</pub-id><pub-id pub-id-type="pmcid">PMC6015099</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuoka</surname><given-names>S</given-names></name><etal/></person-group><article-title>Age modified relationship between modifiable risk factors and the risk of atrial fibrillation</article-title><source>Circ. Arrhythmia Electrophysiol.</source><year>2022</year><volume>15</volume><issue>1</issue><fpage>e010409</fpage><pub-id pub-id-type="doi">10.1161/CIRCEP.121.010409</pub-id><pub-id pub-id-type="pmid">34939429</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Matsuoka, S. et al. Age modified relationship between modifiable risk factors and the risk of atrial fibrillation. <italic toggle="yes">Circ. Arrhythmia Electrophysiol. </italic><bold>15</bold> (1), e010409. 10.1161/CIRCEP.121.010409 (2022).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCEP.121.010409</pub-id><pub-id pub-id-type="pmid">34939429</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>F</given-names></name><etal/></person-group><article-title>Predictive factors of hemorrhage after thrombolysis in patients with acute ischemic stroke</article-title><source>Front. Neurol.</source><year>2020</year><volume>11</volume><issue>November</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">33224083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.551157</pub-id><pub-id pub-id-type="pmcid">PMC7671058</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Sun, F. et al. Predictive factors of hemorrhage after thrombolysis in patients with acute ischemic stroke. <italic toggle="yes">Front. Neurol. </italic><bold>11</bold> (November), 1&#8211;6 (2020).<pub-id pub-id-type="pmid">33224083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2020.551157</pub-id><pub-id pub-id-type="pmcid">PMC7671058</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez-Sab&#237;n</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator&#8211;treated patients</article-title><source>Stroke</source><year>2003</year><volume>34</volume><issue>5</issue><fpage>1235</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1161/01.STR.0000068406.30514.31</pub-id><pub-id pub-id-type="pmid">12677014</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Alvarez-Sab&#237;n, J. et al. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator&#8211;treated patients. <italic toggle="yes">Stroke </italic><bold>34</bold> (5), 1235&#8211;1241 (2003).<pub-id pub-id-type="pmid">12677014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.STR.0000068406.30514.31</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>HPJ</given-names></name><etal/></person-group><article-title>Baseline NIH stroke scale score strongly predicts outcome after stroke: a report of the trial of Org 10172 in acute stroke treatment (TOAST)</article-title><source>Neurology</source><year>1999</year><volume>53</volume><issue>1</issue><fpage>126</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1212/WNL.53.1.126</pub-id><pub-id pub-id-type="pmid">10408548</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Adams, H. P. J. et al. Baseline NIH stroke scale score strongly predicts outcome after stroke: a report of the trial of Org 10172 in acute stroke treatment (TOAST). <italic toggle="yes">Neurology </italic><bold>53</bold> (1), 126&#8211;131 (1999).<pub-id pub-id-type="pmid">10408548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.53.1.126</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the SHINE randomized clinical trial</article-title><source>JAMA</source><year>2019</year><volume>322</volume><issue>4</issue><fpage>326</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1001/jama.2019.9346</pub-id><pub-id pub-id-type="pmid">31334795</pub-id><pub-id pub-id-type="pmcid">PMC6652154</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Johnston, K. C. et al. Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the SHINE randomized clinical trial. <italic toggle="yes">JAMA </italic><bold>322</bold> (4), 326&#8211;335. 10.1001/jama.2019.9346 (2019).<pub-id pub-id-type="pmid">31334795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.9346</pub-id><pub-id pub-id-type="pmcid">PMC6652154</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tawil</surname><given-names>S</given-names></name><name name-style="western"><surname>El, Muir</surname><given-names>KW</given-names></name></person-group><article-title>Thrombolysis and thrombectomy for acute ischaemic stroke</article-title><source>Clin. Med.</source><year>2017</year><volume>17</volume><issue>2</issue><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.7861/clinmedicine.17-2-161</pub-id><pub-id pub-id-type="pmcid">PMC6297620</pub-id><pub-id pub-id-type="pmid">28365630</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Tawil, S. &amp; El, Muir, K. W. Thrombolysis and thrombectomy for acute ischaemic stroke. <italic toggle="yes">Clin. Med. </italic><bold>17</bold> (2), 161&#8211;165 (2017).<pub-id pub-id-type="doi" assigning-authority="pmc">10.7861/clinmedicine.17-2-161</pub-id><pub-id pub-id-type="pmcid">PMC6297620</pub-id><pub-id pub-id-type="pmid">28365630</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qureshi</surname><given-names>AI</given-names></name></person-group><article-title>Acute hypertensive response in patients with stroke pathophysiology and management</article-title><source>Circulation</source><year>2008</year><volume>18</volume><issue>2</issue><fpage>176</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.723874</pub-id><pub-id pub-id-type="pmid">18606927</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Qureshi, A. I. Acute hypertensive response in patients with stroke pathophysiology and management. <italic toggle="yes">Circulation </italic><bold>18</bold> (2), 176&#8211;187 (2008).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.107.723874</pub-id><pub-id pub-id-type="pmid">18606927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Elgamal, S. et al. The effect of lacosamide on calcitonin gene-related peptide serum level in episodic migraine patients: a randomized, controlled trial. <italic toggle="yes">Acta Neurol. Belg.</italic> (0123456789). 10.1007/s13760-024-02499-9 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13760-024-02499-9</pub-id><pub-id pub-id-type="pmcid">PMC11139685</pub-id><pub-id pub-id-type="pmid">38502425</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>YS</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Di, Zeng</surname><given-names>ZH</given-names></name></person-group><article-title>Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review</article-title><source>Lipids Health Dis.</source><year>2020</year><volume>19</volume><issue>1</issue><fpage>23</fpage><pub-id pub-id-type="doi">10.1186/s12944-019-1171-8</pub-id><pub-id pub-id-type="pmid">32035485</pub-id><pub-id pub-id-type="pmcid">PMC7007679</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Yao, Y. S., Li, T. &amp; Di, Zeng, Z. H. Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. <italic toggle="yes">Lipids Health Dis. </italic><bold>19</bold> (1), 23. 10.1186/s12944-019-1171-8 (2020).<pub-id pub-id-type="pmid">32035485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12944-019-1171-8</pub-id><pub-id pub-id-type="pmcid">PMC7007679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grau</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Fever and infection early after ischemic stroke</article-title><source>J. Neurol. Sci.</source><year>1999</year><volume>171</volume><issue>2</issue><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/S0022-510X(99)00261-0</pub-id><pub-id pub-id-type="pmid">10581377</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Grau, A. J. et al. Fever and infection early after ischemic stroke. <italic toggle="yes">J. Neurol. Sci. </italic><bold>171</bold> (2), 115&#8211;120 (1999).<pub-id pub-id-type="pmid">10581377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0022-510x(99)00261-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grotta</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Clinical deterioration following improvement in the NINDS rt-PA stroke trial</article-title><source>Stroke</source><year>2001</year><volume>32</volume><issue>3</issue><fpage>661</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1161/01.STR.32.3.661</pub-id><pub-id pub-id-type="pmid">11239184</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Grotta, J. C. et al. Clinical deterioration following improvement in the NINDS rt-PA stroke trial. <italic toggle="yes">Stroke </italic><bold>32</bold> (3), 661&#8211;668. 10.1161/01.STR.32.3.661 (2001).<pub-id pub-id-type="pmid">11239184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.str.32.3.661</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aref</surname><given-names>HM</given-names></name><etal/></person-group><article-title>A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke</article-title><source>Neurol. Sci.</source><year>2023</year><volume>44</volume><issue>2</issue><fpage>765</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1007/s10072-022-06525-7</pub-id><pub-id pub-id-type="pmid">36446950</pub-id><pub-id pub-id-type="pmcid">PMC9842543</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Aref, H. M. et al. A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke. <italic toggle="yes">Neurol. Sci. </italic><bold>44</bold> (2), 765&#8211;771. 10.1007/s10072-022-06525-7 (2023).<pub-id pub-id-type="pmid">36446950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10072-022-06525-7</pub-id><pub-id pub-id-type="pmcid">PMC9842543</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeinhom</surname><given-names>MG</given-names></name><etal/></person-group><article-title>A pilot study of the ticagrelor role in ischemic stroke secondary prevention</article-title><source>Eur. Neurol.</source><year>2022</year><volume>85</volume><issue>1</issue><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1159/000518786</pub-id><pub-id pub-id-type="pmid">34515113</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Zeinhom, M. G. et al. A pilot study of the ticagrelor role in ischemic stroke secondary prevention. <italic toggle="yes">Eur. Neurol. </italic><bold>85</bold> (1), 50&#8211;55 (2022).<pub-id pub-id-type="pmid">34515113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000518786</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toni</surname><given-names>D</given-names></name><etal/></person-group><article-title>Hemorrhagic transformation of brain infarct</article-title><source>Neurology</source><year>1996</year><volume>46</volume><issue>2</issue><fpage>341</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1212/WNL.46.2.341</pub-id><pub-id pub-id-type="pmid">8614491</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Toni, D. et al. Hemorrhagic transformation of brain infarct. <italic toggle="yes">Neurology </italic><bold>46</bold> (2), 341&#8211;345 (1996).<pub-id pub-id-type="pmid">8614491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.46.2.341</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arboix</surname><given-names>A</given-names></name><name name-style="western"><surname>Alioc</surname><given-names>J</given-names></name></person-group><article-title>Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis</article-title><source>Curr. Cardiol. Rev.</source><year>2010</year><volume>6</volume><issue>3</issue><fpage>150</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.2174/157340310791658730</pub-id><pub-id pub-id-type="pmid">21804774</pub-id><pub-id pub-id-type="pmcid">PMC2994107</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Arboix, A. &amp; Alioc, J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. <italic toggle="yes">Curr. Cardiol. Rev. </italic><bold>6</bold> (3), 150&#8211;161 (2010).<pub-id pub-id-type="pmid">21804774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/157340310791658730</pub-id><pub-id pub-id-type="pmcid">PMC2994107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strbian</surname><given-names>D</given-names></name><etal/></person-group><article-title>Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis</article-title><source>Neurology</source><year>2011</year><volume>77</volume><issue>4</issue><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3182267b8c</pub-id><pub-id pub-id-type="pmid">21715707</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Strbian, D. et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. <italic toggle="yes">Neurology </italic><bold>77</bold> (4), 341&#8211;348 (2011).<pub-id pub-id-type="pmid">21715707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182267b8c</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lansberg</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke</article-title><source>Stroke</source><year>2007</year><volume>38</volume><issue>8</issue><fpage>2275</fpage><lpage>2278</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.106.480475</pub-id><pub-id pub-id-type="pmid">17569874</pub-id><pub-id pub-id-type="pmcid">PMC3985814</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Lansberg, M. G. et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. <italic toggle="yes">Stroke </italic><bold>38</bold> (8), 2275&#8211;2278 (2007).<pub-id pub-id-type="pmid">17569874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.106.480475</pub-id><pub-id pub-id-type="pmcid">PMC3985814</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Predictors of post-thrombolysis symptomatic intracranial hemorrhage in Chinese patients with acute ischemic stroke</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><issue>9</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0184646</pub-id><pub-id pub-id-type="pmcid">PMC5602541</pub-id><pub-id pub-id-type="pmid">28922363</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Liu, M., Pan, Y., Zhou, L. &amp; Wang, Y. Predictors of post-thrombolysis symptomatic intracranial hemorrhage in Chinese patients with acute ischemic stroke. <italic toggle="yes">PLoS One </italic><bold>12</bold> (9), 1&#8211;10 (2017).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0184646</pub-id><pub-id pub-id-type="pmcid">PMC5602541</pub-id><pub-id pub-id-type="pmid">28922363</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nisar</surname><given-names>T</given-names></name><name name-style="western"><surname>Hanumanthu</surname><given-names>R</given-names></name><name name-style="western"><surname>Khandelwal</surname><given-names>P</given-names></name></person-group><article-title>Symptomatic intracerebral hemorrhage after intravenous thrombolysis: predictive factors and validation of prediction models</article-title><source>J. Stroke Cerebrovasc. Dis.</source><year>2019</year><volume>28</volume><issue>11</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2019.104360</pub-id><pub-id pub-id-type="pmid">31501036</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Nisar, T., Hanumanthu, R. &amp; Khandelwal, P. Symptomatic intracerebral hemorrhage after intravenous thrombolysis: predictive factors and validation of prediction models. <italic toggle="yes">J. Stroke Cerebrovasc. Dis. </italic><bold>28</bold> (11), 1&#8211;8 (2019).<pub-id pub-id-type="pmid">31501036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jstrokecerebrovasdis.2019.104360</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chenna</surname><given-names>V</given-names></name><etal/></person-group><article-title>Predictors of intracerebral hemorrhage in acute stroke patients receiving intravenous recombinant tissue plasminogen activator</article-title><source>Ann. Indian Acad. Neurol.</source><year>2018</year><volume>21</volume><issue>3</issue><fpage>214</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.4103/aian.AIAN_228_17</pub-id><pub-id pub-id-type="pmid">30258265</pub-id><pub-id pub-id-type="pmcid">PMC6137634</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Chenna, V. et al. Predictors of intracerebral hemorrhage in acute stroke patients receiving intravenous recombinant tissue plasminogen activator. <italic toggle="yes">Ann. Indian Acad. Neurol. </italic><bold>21</bold> (3), 214&#8211;219 (2018).<pub-id pub-id-type="pmid">30258265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/aian.AIAN_228_17</pub-id><pub-id pub-id-type="pmcid">PMC6137634</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Predictors for symptomatic intracranial hemorrhage after intravenous thrombolysis with acute ischemic stroke within 6&#160;h in northern China: a multicenter, retrospective study</article-title><source>BMC Neurol.</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1186/s12883-021-02534-9</pub-id><pub-id pub-id-type="pmid">34980004</pub-id><pub-id pub-id-type="pmcid">PMC8722135</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Xue, Y. et al. Predictors for symptomatic intracranial hemorrhage after intravenous thrombolysis with acute ischemic stroke within 6&#160;h in northern China: a multicenter, retrospective study. <italic toggle="yes">BMC Neurol. </italic><bold>22</bold> (1), 1&#8211;7. 10.1186/s12883-021-02534-9 (2022).<pub-id pub-id-type="pmid">34980004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12883-021-02534-9</pub-id><pub-id pub-id-type="pmcid">PMC8722135</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leira</surname><given-names>R</given-names></name><etal/></person-group><article-title>A higher body temperature is associated with haemorrhagic transformation in patients with acute stroke untreated with recombinant tissue-type plasminogen activator (rtPA)</article-title><source>Clin. Sci. (Lond.)</source><year>2012</year><volume>122</volume><issue>3</issue><fpage>113</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1042/CS20110143</pub-id><pub-id pub-id-type="pmid">21861843</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Leira, R. et al. A higher body temperature is associated with haemorrhagic transformation in patients with acute stroke untreated with recombinant tissue-type plasminogen activator (rtPA). <italic toggle="yes">Clin. Sci. (Lond.) </italic><bold>122</bold> (3), 113&#8211;119 (2012).<pub-id pub-id-type="pmid">21861843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/CS20110143</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindley</surname><given-names>RI</given-names></name><etal/></person-group><article-title>Alteplase for Acute ischemic stroke</article-title><source>Stroke</source><year>2015</year><volume>46</volume><issue>3</issue><fpage>746</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.114.006573</pub-id><pub-id pub-id-type="pmid">25613308</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Lindley, R. I. et al. Alteplase for Acute ischemic stroke. <italic toggle="yes">Stroke </italic><bold>46</bold> (3), 746&#8211;756 (2015).<pub-id pub-id-type="pmid">25613308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.114.006573</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escudero-Mart&#237;nez</surname><given-names>I</given-names></name><etal/></person-group><article-title>Association of cholesterol levels with hemorrhagic transformation and cerebral edema after reperfusion therapies</article-title><source>Eur. Stroke J.</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>294</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1177/23969873221148229</pub-id><pub-id pub-id-type="pmid">37021184</pub-id><pub-id pub-id-type="pmcid">PMC10069196</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Escudero-Mart&#237;nez, I. et al. Association of cholesterol levels with hemorrhagic transformation and cerebral edema after reperfusion therapies. <italic toggle="yes">Eur. Stroke J. </italic><bold>8</bold> (1), 294&#8211;300 (2023).<pub-id pub-id-type="pmid">37021184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/23969873221148229</pub-id><pub-id pub-id-type="pmcid">PMC10069196</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van den Berg</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Admission blood pressure and clinical outcomes in patients with acute ischaemic stroke treated with intravenous alteplase and endovascular treatment versus endovascular treatment alone: a MR CLEAN-IV substudy</article-title><source>Eur. Stroke J.</source><year>2023</year><volume>8</volume><issue>3</issue><fpage>647</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1177/23969873231173274</pub-id><pub-id pub-id-type="pmid">37641554</pub-id><pub-id pub-id-type="pmcid">PMC10472956</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">van den Berg, S. A. et al. Admission blood pressure and clinical outcomes in patients with acute ischaemic stroke treated with intravenous alteplase and endovascular treatment versus endovascular treatment alone: a MR CLEAN-IV substudy. <italic toggle="yes">Eur. Stroke J. </italic><bold>8</bold> (3), 647&#8211;654 (2023).<pub-id pub-id-type="pmid">37641554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/23969873231173274</pub-id><pub-id pub-id-type="pmcid">PMC10472956</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dor&#328;&#225;k</surname><given-names>T</given-names></name><etal/></person-group><article-title>Posterior vs. anterior circulation infarction: demography, outcomes, and frequency of Hemorrhage after Thrombolysis</article-title><source>Int. J. Stroke</source><year>2015</year><volume>10</volume><issue>8</issue><fpage>1224</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1111/ijs.12626</pub-id><pub-id pub-id-type="pmid">26310390</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Dor&#328;&#225;k, T. et al. Posterior vs. anterior circulation infarction: demography, outcomes, and frequency of Hemorrhage after Thrombolysis. <italic toggle="yes">Int. J. Stroke </italic><bold>10</bold> (8), 1224&#8211;1228 (2015).<pub-id pub-id-type="pmid">26310390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijs.12626</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cronin</surname><given-names>CA</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N</given-names></name><name name-style="western"><surname>Morovati</surname><given-names>T</given-names></name><name name-style="western"><surname>Hermann</surname><given-names>LD</given-names></name><name name-style="western"><surname>Sheth</surname><given-names>KN</given-names></name></person-group><article-title>No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria</article-title><source>Stroke</source><year>2012</year><volume>43</volume><issue>6</issue><fpage>1684</fpage><lpage>1686</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.112.656587</pub-id><pub-id pub-id-type="pmid">22535272</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Cronin, C. A., Shah, N., Morovati, T., Hermann, L. D. &amp; Sheth, K. N. No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria. <italic toggle="yes">Stroke </italic><bold>43</bold> (6), 1684&#8211;1686 (2012).<pub-id pub-id-type="pmid">22535272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.112.656587</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>X</given-names></name><name name-style="western"><surname>George</surname><given-names>MG</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>C</given-names></name></person-group><article-title>Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008&#8211;2012</article-title><source>Int. J. Stroke off J. Int. Stroke Soc.</source><year>2014</year><volume>9</volume><issue>6</issue><fpage>728</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1111/ijs.12155</pub-id><pub-id pub-id-type="pmcid">PMC4451118</pub-id><pub-id pub-id-type="pmid">24024962</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Tong, X., George, M. G., Yang, Q. &amp; Gillespie, C. Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008&#8211;2012. <italic toggle="yes">Int. J. Stroke off J. Int. Stroke Soc. </italic><bold>9</bold> (6), 728&#8211;734 (2014).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijs.12155</pub-id><pub-id pub-id-type="pmcid">PMC4451118</pub-id><pub-id pub-id-type="pmid">24024962</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Khaled</surname><given-names>M</given-names></name><name name-style="western"><surname>Matthis</surname><given-names>C</given-names></name><name name-style="western"><surname>Eggers</surname><given-names>J</given-names></name></person-group><article-title>Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke</article-title><source>J. Stroke Cerebrovasc. Dis. Off J. Natl. Stroke Assoc.</source><year>2014</year><volume>23</volume><issue>1</issue><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2012.04.004</pub-id><pub-id pub-id-type="pmid">22578915</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Al-Khaled, M., Matthis, C. &amp; Eggers, J. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke. <italic toggle="yes">J. Stroke Cerebrovasc. Dis. Off J. Natl. Stroke Assoc. </italic><bold>23</bold> (1), 7&#8211;11 (2014).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jstrokecerebrovasdis.2012.04.004</pub-id><pub-id pub-id-type="pmid">22578915</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kastrup</surname><given-names>A</given-names></name><etal/></person-group><article-title>Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke</article-title><source>Stroke</source><year>2008</year><volume>39</volume><fpage>2385</fpage><lpage>2387</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.107.505420</pub-id><pub-id pub-id-type="pmid">18556588</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Kastrup, A. et al. Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke. <italic toggle="yes">Stroke </italic><bold>39</bold>, 2385&#8211;2387 (2008).<pub-id pub-id-type="pmid">18556588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.107.505420</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arboix</surname><given-names>A</given-names></name><name name-style="western"><surname>Garc&#237;a-Eroles</surname><given-names>L</given-names></name><name name-style="western"><surname>Massons</surname><given-names>J</given-names></name><name name-style="western"><surname>Oliveres</surname><given-names>M</given-names></name><name name-style="western"><surname>Targa</surname><given-names>C</given-names></name></person-group><article-title>Lacunar infarcts in patients aged 85 years and older</article-title><source>Acta Neurol. Scand.</source><year>2000</year><volume>101</volume><issue>1</issue><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0404.2000.00005.x</pub-id><pub-id pub-id-type="pmid">10660148</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Arboix, A., Garc&#237;a-Eroles, L., Massons, J., Oliveres, M. &amp; Targa, C. Lacunar infarcts in patients aged 85 years and older. <italic toggle="yes">Acta Neurol. Scand. </italic><bold>101</bold> (1), 25&#8211;29 (2000).<pub-id pub-id-type="pmid">10660148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1034/j.1600-0404.2000.00005.x</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>